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ABSTRACT 
 Multiple brain disorders are associated with hypoinhibition of neural circuits that 
are controlled by inhibitory neurons using the neurotransmitter γ-aminobutyric acid 
(GABA).  GABA activates type A receptors (GABARs) to mediate the majority of 
inhibitory neurotransmission and changes in GABAR subunit composition have profound 
effects on brain function. In fact, down-regulation of one of the three β isoforms, β1, is 
associated with alcoholism, autism, epilepsy, schizophrenia, and bipolar disorder. These 
conditions also present with mitochondrial defects and metabolic dysregulation.  
  In the first Aim of my thesis, I ask whether the core promoter of the human 
GABAR β1 subunit gene (GABRB1) can be regulated by the same transcription factor, 
the nuclear respiratory factor 1 (NRF-1) that controls oxidative phosphorylation and 
mitochondrial biogenesis in neurons. The ENCODE database of NRF-1 binding in human 
embryonic stem cells was used to identify an interaction of NRF-1 with GABRB1. Using 
a variety of approaches: electro mobility shift, promoter/reporter luciferase assays, gene 
silencing and bioinformatics, we demonstrate that GABRB1 contains a canonical NRF-1 
element responsible for the majority of GABRB1 promoter- luciferase activity in 
transfected primary neurons. Moreover, we show that endogenous NRF-1 is responsible 
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for a substantial amount of luciferase activity in our studies.  Altogether, our results 
suggest GABRB1 is a target gene for NRF-1, providing a possible link between 
mitochondria related energy metabolism and transcriptional regulation of β1-containing 
GABARs in neurological disease. 
 Synthesis of NRF-1 is regulated by the transcription factor cAMP response 
element binding protein (CREB), an important memory molecule implicated in multiple 
brain disorders. The second Aim of my thesis was to develop a molecular sensor that can 
be used in living neurons to signal the presence of CREB dependent gene regulation. We 
employ a split complement bioluminescent sensor to monitor interaction of protein 
surfaces that link CREB with its co-factor CBP and demonstrate that it can detect 
activation of CREB via its serine 133 phosphorylation site and activation through an 
undiscovered mechanism.  We also show that this sensor can be used to monitor BDNF 
signaling providing the foundation for its future use in in vivo models of disease where 
BDNF is implicated. 
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PREFACE 
This thesis is organized in the form of a general introduction to my areas of 
interest, a methods section that contains information relevant to the complete thesis 
research, and two research projects that are presented in the form of manuscripts that 
address the following two specific Aims: 
 
Aim 1. To determine whether the core promoter region of the human GABAR 1 
subunit gene (GABRB1) can be regulated by the same transcription factor, the nuclear 
respiratory factor 1 (NRF-1) that controls oxidative phosphorylation and mitochondrial 
biogenesis in neurons. 
 
Aim 2.  To develop a molecular sensor that can be used in living neurons to signal 
the presence of CREB dependent gene regulation.   
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CHAPTER I. INTRODUCTION 
 
Chapter 1 is organized to introduce the areas of metabolism and neurobiology that 
I reviewed during the progression of my thesis research. It begins with the role of Nuclear 
Respiratory Factor 1 (NRF-1) in mediating energy metabolism and neural activity. It 
continues with an overview of epilepsy and the GABAR subunit changes that most likely 
contribute to an imbalance in inhibitory neurotransmission. The ideas presented in these 
two areas form the basis and motivation for Aim 1 of my thesis: To determine whether 
the core promoter region of the human GABAR 1 subunit gene (GABRB1) can be 
regulated by the same transcription factor, the nuclear respiratory factor 1 (NRF-1), that 
controls oxidative phosphorylation and mitochondrial biogenesis in neurons.  
Next, I review the salient features of activity-dependent gene regulation as 
mediated by the cAMP regulatory binding protein (CREB) and as informed by 
biochemical analysis.  This provides the background for Aim 2 of my thesis:  To develop 
a molecular sensor that can be used in living neurons to signal the presence of CREB 
dependent gene regulation. 
A. Neuronal activity and energy metabolism 
1. Energy metabolism: a coordination between two genomes  
Oxidative phosphorylation (OXPHOS) is a cellular process that takes place in the 
mitochondria, in which ATP is formed from the combustion of glucose into carbon 
dioxide and water. During OXPHOS, ATP is synthesized by ATP synthase when protons 
flow across the inner mitochondrial membrane into the mitochondrial matrix down their 
concentration gradient and transmembrane electrical potential. This pH gradient is 
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maintained through a set of enzyme complexes, known as the electron transport chain 
(ETC), that transfers electrons from NADH or FADH2 to molecular oxygen, while 
pumping protons back across the inner membrane against the established gradient. The 
last protein complex of the ETC, cytochrome c oxidase (COX) or Complex IV, catalyzes 
the final transfer of electrons from cytochrome c (Cyt c) to oxygen, returning Cyt c to its 
oxidized state, reducing oxygen to water, resulting in a net translocation of protons from 
the matrix into the intermembrane space. The subunits that constitute COX, as well as 
ETC Complexes I, and III, are encoded by both the nuclear and mitochondrial genomes 
(Kadenbach, Jarausch et al. 1983, Au, Seo et al. 1999, Scarpulla 2006). As such, it is 
essential that a proper coordination and communication between the nucleus and the ATP 
generating organelle, the mitochondria, must occur in order to maintain energy balance.  
This coordination is especially important in neurons whose energy demands are 
extremely high and must be met so that they can adapt to the needs of a continually 
changing extracellular environment. 
2. Nuclear-encoded regulators of mitochondrial biogenesis: NRF-1 and PGC-1α 
2.1 NRF-1.  
One of the workhorses that bridges nuclear-mitochondrial communication is the 
transcription factor, nuclear respiratory factor 1 (NRF-1). The full length 503-amino acid 
human NRF-1 is a nuclear-encoded gene, first discovered as a transcriptional regulator of 
the Cycs gene that encode cytochrome c (Dudek 2007). It has since been characterized as 
a positive transcriptional regulator of COX subunit genes (Dhar, Ongwijitwat et al. 2008, 
Wong-Riley 2012) and other respiratory genes (Evans and Scarpulla 1990, Scarpulla 
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2008), underscoring its major role in mitochondrial function. The contribution of NRF-1 
in cellular respiration goes beyond OXPHOS, as its targets include those responsible for 
mitochondrial biogenesis, the birth of new mitochondria. Mitochondrial biogenesis 
occurs in response to energy demand, thermogenesis, and oxidative stress. This cellular 
program is directed by a limited number of nucleus-encoded factors (Tfam, TFB1M, 
TFB2M, and mTERF). In preparation for mitochondrial biogenesis, the mitochondrial 
transcription factor A (Tfam) is synthesized to drive the transcription and replication of 
mitochondrial DNA (mtDNA) replication (Scarpulla 2008). The results of these studies 
suggest that the generation and establishment of functioning mitochondria require the 
expression of both mitochondrial-encoded and nuclear-encoded genes (Evans and 
Scarpulla 1989, Scarpulla 2006, Scarpulla 2008, Scarpulla 2011). 
As a transcription factor that mediates nuclear-mitochondrial interactions, NRF-1 
is highly conserved between species, particularly in the amino-terminal half of the 
protein, where it shares high sequence similarity with the developmental regulatory 
factors erect wing (EWG) of Drosophila and P3A2 of sea urchin (Virbasius, Virbasius et 
al. 1993). This particular region of the proteins encompasses the nuclear localization 
(NLS), as well as the DNA binding and dimerization domains. Juxtaposed to the NLS 
sequence, there is a conserved inhibitory domain that was revealed through deletion 
analysis, suggesting that the N-terminus may modulate transcriptional activity (Fazio, 
Bolger et al. 2001, Ramachandran, Yu et al. 2008). In contrast to the N-terminus, its 
carboxy-terminal half, where the transcriptional activation domain lies, is divergent 
across species. Further analysis of the transactivation domain in EWG also showed 
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conservation with NRF-1 (Fazio, Bolger et al. 2001).   
Within the NRF-1 amino-terminus, there are multiple residues for post-
translational modification that affects its function. NRF-1 is phosphorylated on serine 
residues, resulting in enhanced intrinsic binding to DNA and trans-activation function 
(Gugneja and Scarpulla 1997, Herzig, Scacco et al. (2000). Its binding and activity can 
also be stimulated by phosphorylation at Threonine 109 through the PI3K/AKT pathway 
(Piantadosi and Suliman 2006). However, not all phosphorylation sites lead to activation. 
Phosphorylation at serine 47 by Cyclin D1-dependent kinase leads to repression of NRF-
1 expression and activity (Wang, Li et al. 2006). Taken together, these findings highlight 
the importance of the N-terminal domain in the regulation of NRF-1 activity. 
Since dimerization and DNA binding is not required by phosphorylation (Gugneja 
and Scarpulla 1997), this may suggest that NRF-1 is constitutively bound to its targets 
(Ramachandran, Yu et al. 2008). NRF-1 binds to a GC-rich element within its target 
promoters and recognizes the consensus sequence (T/C)GCGCA(C/T)GCGC(A/G). This 
binding motif has been identified as one of those highly represented in core human 
promoter sequences, particularly in TATA-less promoters (Xi, Yu et al. 2007). 
Associated with TATA-less promoters are short interspersed GC-rich DNA sequences, 
called CpG islands, which are sites of transcription initiation (von Beroldingen, Reynolds 
et al. 1984, Rozenberg, Shlyakhtenko et al. 2008). This discovery has led to the proposed 
role of NRF-1 as a transcriptional initiator (Zhang, Yu et al. 2013) in CpG islands, 
exemplified by NRF-1’s capacity to mediate transcriptional initiation of insulin-
degrading enzyme independent of TATA box-binding protein (Zhang, Ding et al. 2012). 
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Recently, a growing number of studies have reported functional NRF-1 binding to genes 
within CpG islands (Gonen and Assaraf 2010, Li, Li et al. 2011, Zhang, Ding et al. 2012) 
suggesting that coordinated control over this region of the genome may link the energy 
demands of the cell to a rapid and adaptive transcriptional response.   
Located on Chromosome 7 in the human genome, NRF-1 is ubiquitously 
expressed, as assessed by in vitro hybridization in rat, with relatively high expression 
levels in the lungs and testis, and moderate expression in the brain (Gopalakrishnan and 
Scarpulla 1995). Homozygous NRF-1 knockout mice exhibit peri-implantation lethality 
between embryonic day E3.5 and E6.5. Upon closer examination, the blastocyst of these 
animals harbor less mitochondria and mitochondrial DNA content, consistent with NRF-
1’s role in regulating TFam (Huo and Scarpulla 2001). In comparison, the heterozygous 
mice appear phenotypically normal, but failure of blastocysts to develop properly in vitro 
was noted. The NRF-1 homologues EWG in drosophila and not really finished (nrf) in 
zebra fish are both implicated as important in early development and associated 
specifically with the central nervous system (CNS) (Huo and Scarpulla 2001). These 
homologous systems suggest that the lethality observed in knockout mice may be due to a 
failure in neural development.   
 2.2 PGC-1α and NRF-1 in neurons 
In addition to NRF-1, there is a master molecular regulator called peroxisome 
proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) that is critical for 
mitochondrial biogenesis (Puigserver, Wu et al. 1998) and the maintenance of energy 
balance. PGC-1α is a coactivator of NRF-1 function, as well as an activator of NRF-1 
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expression. PGC-1α is regulated by various post-translational mechanisms including 
phosphorylation by AMP-activated protein kinase (AMPK) that leads to its activation in 
response to increased AMP/ATP ratio, a marker of energy depletion.  
 The major consumer of oxygen is the brain. For the brain, its source of energy is 
limited to only glucose and ketone bodies. The nervous system is highly dependent on 
OXPHOS (Sokoloff and Kety 1960, Hall, Klein-Flugge et al. 2012). Given that the brain 
is the most energy-dependent organ of the body (Attwell and Laughlin 2001), it is not 
surprising that NRF-1 may be critical to its development and continued health. 
Interestingly, cytochrome c promoter activity is activity-dependent. Neural 
activity-mediated stimulation of cytochrome c occurs via both NRF-1 and the cAMP 
response element binding protein (CREB) in response to synaptic stimulation (Mayr and 
Montminy 2001, Deisseroth and Tsien 2002). NRF-1-mediated expression of cytochrome 
c is calcium-dependent and requires extracellular-signal-regulated kinases ERK1/2 
(Delgado and Owens 2012).    
Brain-derived neurotrophic factor (BDNF), known to support neuronal survival, 
and the growth and differentiation of nascent neurons, stimulates the expression of 
mitochondrial biogenesis markers such as PGC-1α, Tfam, and NRF-1 in cultured 
hippocampal neurons. Stimulation of PGC-1α by BDNF is dependent on mitogen-
activated protein kinase (MAPK) and CREB. In fact, the number of mitochondria in a 
neuron correlates with its spine density, and its number of synapses positively correlates 
with PGC-1α levels (in a model where PGC-1α knock-down reduces spine density) 
(Cheng, Wan et al. 2012). Moreover, PGC-1α has been implicated in the formation and 
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maintenance of neuronal dendritic spines. NRF-1 can also regulate neurite outgrowth 
through its transcriptional regulation of novel genes (Chang and Huang 2004, Chang, 
Chen et al. 2005, Wang, Tong et al. 2013), also reported in neuroblastoma IMR-32 cells 
and hippocampal neurons (Tong, Wang et al. 2013). 
 The transcriptional regulation of NRF-1 in neurons is activity-dependent (Yang, 
Liang et al. 2006) and mediated through AMPK (Yu and Yang 2010), a key enzyme in 
cellular energy homeostasis. Interestingly, reports show that NRF-1, under conditions of 
depolarizing stimulation, regulates expression of receptor subunit genes associated with 
glutamatergic synaptic neurotransmission, such as NR1, NR2B (Dhar and Wong-Riley 
2009), GluR2 (Myers, Peters et al. 1998, Dhar, Liang et al. 2009), and neuronal nitric 
oxide synthase (nNOS) (Myers, Peters et al. 1998, Dhar, Liang et al. 2009). These 
findings further emphasize that neuronal activity and energy metabolism are tightly 
coupled.  
 NRF-1 and/or mitochondrial biogenesis can be induced by various stimuli 
associated with brain disorders. In response to transient hypoxia, there is an increase in 
mitochondrial biogenesis in the brain subcortex of mice, along with an activation of 
NRF-1 and PGC-1α expression (Gutsaeva, Carraway et al. 2008). The molecular 
mechanism of such changes in expression is driven by nNOS and the activation of 
CREB, which through its role as a key transcriptional regulator of synaptic plasticity is 
also implicated in the dysregulation of plasticity seen in epilepsy (Lund, Hu et al. 2008, 
Porter, Lund et al. 2008).  
Mitochondrial biogenesis also occurs in response to inflammation that is induced 
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by lipopolysaccharide and depends upon the upregulation of NRF-1 expression that is 
controlled by NFκB and CREB (Suliman, Sweeney et al. 2010). These reports taken 
together point to a convergence on CREB as a major factor in the control of 
mitochondrial biogenesis, achieved through its upregulation of nuclear genes and its 
translocation from cytoplasm to mitochondria to activate mitochondrial gene 
transcription within neurons (Lee, Kim et al. 2005, De Rasmo, Signorile et al. 2009, De 
Rasmo, Signorile et al. 2010). 
 In addition, a pathway analysis using ENCODE datasets of ChIP-seq, with SK-N-
SH human neuroblastoma cells, suggests a potential role for NRF-1 in Alzheimer’s and 
Parkinson’s disease (Satoh, Kawana et al. 2013) and, consistent with its role in 
neurodegeneration due to impaired metabolism, PGC-1α and BDNF are both implicated 
in the neuropathologies of Alzheimer’s (Arancibia, Silhol et al. 2008, Qin, Haroutunian et 
al. 2009, Zheng, Liao et al. 2010) and Parkinson’s disease (Maswood, Young et al. 2004, 
Zheng, Liao et al. 2010). 
B. Epilepsy  
1. General classification 
Epilepsy is a disorder characterized by an aperiodic recurrence of seizures in 
response to brain injury, a genetic predisposition, or brain malformation. The incidence 
of epilepsy is 44 per 100,000 person-years. Each year, about 125,000 new cases are 
diagnosed. There is a bimodal distribution in the occurrence of the first seizure in the 
population, with one peak occurring in newborn and young children and the second peak 
occurring in patients older than age 65 (DiPiro 2005). However, the underlying cause of 
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the seizures stems from a diversity of etiologies, varying in clinical presentations and 
consequences. Both genetic and acquired factors can contribute to epilepsy, which lead to 
the etiological categorization of idiopathic and symptomatic epilepsies, respectively. Due 
to diverse phenotypes within idiopathic epilepsies, scientists like William Lennox, 
support the idea that there is a “neurobiological spectrum of epilepsies” (Berkovic, 
Mulley et al. 2006). At one end of the spectrum are the idiopathic epilepsies associated 
with a single gene, commonly one that encodes for an ion channel, while the opposite 
spectrum represents epilepsies with no genetic susceptibility for the disease, but arise 
from insults to the brain such as head trauma, stroke, lesions and tumors. Falling in 
between these two extremes are epilepsies that involve multiple genes, those that do not 
follow Mendelian pattern of inheritance and are referred to as cryptogenic. Currently, the 
category “cryptogenic epilepsies” refers to epilepsies that are associated with unknown 
factors. In the perspective of epilepsy being a continuum, “cryptogenic epilepsies” may 
be accounted for by the “interaction of genetic and acquired factors”, in which a 
mechanism that has not been elucidated (Berkovic, Mulley et al. 2006).  
Despite the ongoing challenge in the etiological framework, the numerous 
syndromes are categorized into two broad groups: partial and generalized epilepsies. 
Spontaneous seizures of partial epilepsies have a focal anatomical origin, and can be 
either idiopathic or symptomatic in etiology. They account for 60% of all epilepsies. The 
remaining 40% of epilepsies in the general population are generalized. These epilepsies 
are characterized as having anatomical onsets in both brain hemispheres and, although 
candidate genes remain to be identified, they are considered idiopathic. Partial epilepsies 
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are also subdivided based on whether there is a change in consciousness, with simple 
partial epilepsies being specific to the maintenance of consciousness and complex partial 
to the impairment of consciousness. Due to the complexity of epilepsy presentations, the 
treatment and management of symptoms for patients must reflect the specific syndrome, 
placing emphasis on an accurate diagnosis in order to choose an appropriate 
pharmacotherapy and to act early to reduce seizure events that can be life threatening.       
2.  Treatment 
The goal of pharmacologic therapy for epilepsy is to properly balance drug 
efficacy with drug side effects, where the therapy serves to improve the overall quality of 
life rather than decrease it through disturbances in cognitive function. Effective 
anticonvulsant drugs (ACDs) reduce the number and severity of spontaneous seizures in 
patients protecting them from subsequent brain damage.  
One may ask, what are the physiological consequences of a seizure? The 
prolonged abnormal excitation leads to neuronal toxicity due to the over-exposure of 
neurons to the excitatory neurotransmitter glutamate. As a consequence, there is also an 
increased risk of the brain to ischemia, a condition that leads to the shortage of oxygen 
and nutrients to the brain, ultimately resulting in brain damage. Ideally, only a single 
therapeutic agent should be used to prevent the probability of seizure production in an 
individual. In reality, approximately 65% of patients suffering from epilepsy can manage 
the disease with monotherapy (DiPiro 2005), the remaining patients either require two-
drug regime or are refractory to any drug therapy that is available. When 
pharmacotherapy is not possible, surgery, dietary restriction or vagal nerve stimulation 
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through implantation of a biomedical device is required. Either as a response to disease 
progression or side-effects of pharmacotherapy, epileptic patients often suffer from 
severe neuropsychiatric conditions such as anxiety and depression. 
In general, ACDs control abnormal neuronal activity by elevating the spike 
threshold of neurons to stimuli or by limiting the propagation of the seizure discharge 
from its initial site. The mechanism of action of most ACDs can be categorized into three 
types: modulation of voltage-gated ion channels; enhancement of synaptic inhibition; and 
inhibition of synaptic excitation (Rogawski and Loscher 2004). The types of voltage-
gated ion channels that current molecular therapies target are the sodium channels and 
calcium channels. Enhancement of synaptic inhibition is achieved through the 
modulation of GABAergic neurotransmission. Inhibition of excitation involves the 
blockade of glutamate receptors such as NMDA, kainate (KA) and AMPA. Some ACDs 
target one specific molecular entity, but most have a combination of complex or poorly 
understood mechanisms of action. For example, the drug Topiramate has been shown to 
affect the function of sodium channels, calcium channels, type A GABA receptors 
(GABARs), and Kainate and AMPA receptors (Rogawski and Loscher 2004). In contrast, 
phenytoin, an ACD prescribed for the protection of patients suffering from generalized 
tonic-clonic (GTC) and partial seizures acts primarily through the inactivation of voltage-
gated sodium channels, and specifically by prolonging the refractory period in which 
sodium channels remain unresponsive to opening.  
Along with phenytoin, carbamazepine, oxcarbazepine, lamotrigine, and valproic 
acid are the first-line drugs for treating partial seizures, although they are associated with 
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a variety of side effects that can impair the quality of life. Phenytoin has been used for 
treatment of partial seizures for over 60 years and also as a first-line drug for the 
treatment of status epilepticus, an immediate response of the brain to injury. 
Carbamazepine has been well studied and causes minimal cognitive impairment, 
although chronic use has been associated with altered bone mineral density and liver 
toxicity. Structurally similar to carbamazepine, oxcarbazepine, however, is a prodrug that 
is converted to the active 10-monohydrate derivative. Despite similar mechanism of 
action with carbamazepine, oxcarbazepine appears to modulate N- and P-type Ca2+ 
channels (DiPiro 2005). Although rare, oxcarbazepine and carbamazepine can cause 
rashes and hyponatremia. Neither drug is effective against “absence” or myoclonic 
seizures. In contrast to the seizure specific targets, lamotrigine is a rather broad spectrum 
ACD, having efficacy in partial seizures and several types of generalized seizures. The 
drug is also useful as an adjunctive treatment in partial seizure patients.  
Another broad-spectrum ACD is valproic acid, which is a first-line drug for both 
partial and primary generalized seizures, but can be toxic if taken chronically. The 
pharmacology and mechanism of action in the treatment of epileptic seizures is unclear. 
Initially, valproic acid was thought to assert its anticonvulsant property through altering 
the synthesis and degradation of GABA. It has now been shown that it may exert its 
affects via the potentiation of postsynaptic GABA responses and may also affect 
potassium channels (DiPiro 2005). In addition, Valproate alters expression of vesicular 
glutamate transporter 1 (VGLUT1) and presynaptic glutamate release; increases 
expression of the excitatory amino-acid transporter (EAAT), and alters the function of 
  
13 
glutamate receptors (Sanacora, Zarate et al. 2008). Valproate has also been used in the 
treatment of other brain conditions such as migraine headaches and bipolar disorder. As 
Valproate is a histone deacetylase (HDAC) inhibitor, it remains to be determined whether 
its long-term effects are due to a change in genome expression. Major side effects that 
lead to a lack of patient compliance include significant weight gain, multiple drug-drug 
interactions, tremor, pancreatitis, and polycystic ovary disease.     
Augmentation in inhibitory neurotransmission includes increasing CNS 
concentrations of GABA and potentiating the effects of GABA at its receptor. The latter 
is achieved through a class of drugs known as benzodiazepines that modulate GABARs 
by increasing their affinity for GABA. There is also evidence of felbamate and 
topiramate acting as positive modulators of GABARs (Rogawski and Loscher 2004). The 
concentration of GABA in the brain is controlled by the enzymes glutamate 
decarboxylase (GAD) and GABA transaminase (GABA-T). The GABA analogue, 
vigabatrin (γ-vinyl GABA) irreversibly inhibits GABA-T, reducing GABA degradation, 
leading to a large increase in brain GABA levels. The ACD tiagabine also decreases the 
removal of GABA from the synapse, however, it does this by inhibition of GABA 
reuptake at the GABA transporter (GAT1).   
Efforts to decrease excitatory neurotransmission are primarily focused on 
decreasing (or antagonizing) glutamate and aspartate neurotransmission. The specific 
receptors of interests are the NMDA receptor, AMPA receptor and Kainate receptors. 
These mechanisms are reflected in drugs like felbamate (inhibits NMDA receptors), 
topiramate, phenobarbital (AMPA inhibition) and both kainite and AMPA receptors. 
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Drugs that reduce corticothalmic T-type calcium currents, like valproic acid and 
ethosuximide, are effective against generalized absence seizures.  
Overall, the greatest issue with drug therapy for epilepsy is the side effects that 
influence patient compliance. The non-life-threatening side effects are generally dose-
dependent. Other adverse effects include sedation, dizziness, altered vision, difficulty 
focusing. Long-term adverse effects lead to bone disorders such as osteomalacia and 
osteoporosis. A proposed etiology suggests that treatment interferes with vitamin D 
metabolism, reflected in laboratory tests in increased alkaline phosphatase concentration, 
decreased blood calcium and 25-OH vitamin D concentration (DiPiro 2005).  
Again, one must emphasize that the current ACDs do not prevent the 
development or progression of epilepsy. In addition, there are patients who are resistant 
to all drugs. Therefore, there is an urgent need to develop new therapeutic targets for this 
group of patients, working towards prevention of epilepsy in patients at risk and disease 
modification drugs, as well as symptomatic treatment (Bethmann, Brandt et al. 2007, 
Loscher 2007)(Loscher W. et al., 2007). Surprisingly, for individuals who are drug-
resistant, like those suffering from temporal lobe epilepsy (TLE), half of them achieve 
seizure control through the “ketogenic diet”; a diet that substitutes fats and protein to 
obtain an equivalent calorie intake from foods containing carbohydrates. Due to the 
response of patients to dietary manipulation, Garriga-Canut, M. et al. consider metabolic 
pathways as targets for future pharmacological intervention in the treatment of epilepsy.  
In particular, investigators have studied the effects of the glycolytic inhibitor 2-
deoxy-D-glucose (2DG) in a rat model of TLE, where they have shown that 2DG blocks 
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seizure-induced increases in the expression of brain-derived neurotrophic factor and its 
receptor, TrkB. 2DG displays anticonvulsant and antiepileptic properties, suggesting that 
antiglycolytic compounds may represent a new class of drugs for treating epilepsy 
(Garriga-Canut, Schoenike et al. 2006). 2DG differs from glucose in that a hydroxyl 
group at the C2 position has been replaced by a hydrogen atom. The successful use of 
2DG in this model is associated with its increase in the antiepileptic threshold and 
decrease in the progression of kindling, respectively, suggesting that targeting pathways 
of energy metabolism can control seizures. By targeting metabolism, remodeling 
chromatin structure, and altering gene expression, the authors suggest 2DG may represent 
the founding member of a new class of antiepileptic drugs. 
Similarly, another group has found that ketone bodies reduce the firing rate of 
neurons in the rodent substantia nigra pars reticulata, a region in the brain that may 
control the spread of seizures. Results of the study indicate that the ketogenic diet may 
work by activating neuronal KATP channels, thereby reducing the electrical activity of 
neurons (Ma, Berg et al. 2007). Consistent with a role for potassium channels as a novel 
target for future epilepsy, retigabine is a first-in-class potassium-channel opener that has 
been developed. Retigabine is thought to reduce susceptibility for epileptic seizures 
primarily by opening neuronal voltage-gated potassium channels that allow potassium 
ions to flow out of the cell, increasing the threshold for excitation, and thereby decreasing 
cellular excitability. Specifically, retigabine activates neuronal KCNQ-type K+ channels, 
a gene product involved in idiopathic epilepsy (Steinlein 2004).  
Finally, there is a drug named gabapentin, which was synthesized to be a GABA 
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agonist but was later discovered that it did not act at the GABA receptor but rather as a 
modulator of voltage-sensitive Ca2+ channels that indirectly increase GABA levels in the 
brain (Taylor, Gee et al. 1998). Still, the exact mechanism of action is unknown. 
Nonetheless, gabapentin is effective for partial seizures as an alternative therapy, with 
and without secondary generalization, when used in addition to other antiseizure 
medications (Goodman, Gilman et al. 2006). Related to gabapentin in structure is the 
drug pregabalin that is in clinical trials.  It was identified through investigations of 
alkylated analogues of GABA. In preclinical models of epilepsy and neuropathic pain, 
pregabalin was found more potent than gabapentin (Dworkin and Kirkpatrick 2005).  
3. Temporal lobe epilepsy (TLE) and animal models 
One form of epilepsy prevalent in adults, known as temporal lobe epilepsy (TLE), 
consists of seizures that originate focally in the temporal lobe. These seizures frequently 
lead to impaired consciousness and cognitive impairment such as memory disruption 
(Bell, Lin et al. 2011). Although approximately 65-70% of patients suffering from 
epilepsy can manage or minimize seizure occurrences with a single therapeutic agent, the 
remaining patients either require multi-drug treatments or are entirely refractory to 
current ACDs. Remarkably, for those who are drug-resistant, a common struggle 
confronted by TLE patients, seizure control can be achieve through a dietary regimen 
known as the “ketogenic diet”; a diet that substitutes fats and protein to obtain an 
equivalent caloric intake from a typical carbohydrate-rich diet, as described earlier in this 
chapter. The success of the ketogenic diet suggests an energetic and metabolic 
component to the mechanism of epileptogenesis.  
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The initial injuries leading to chronic acquired epilepsies converge upon many 
cellular and molecular changes such as those that increase production of reactive oxygen 
species, oxidative stress and mitochondrial dysfunction. Potential sequelae to these 
changes are dysregulated energy and cellular metabolism. Epilepsy has been associated 
with oxidative stress, mitochondrial dysfunction, as well as neuronal death depending on 
the region of the brain (Waldbaum and Patel 2010). These interconnected cellular 
processes can culminate in decreasing ATP supply, altering cellular energy and 
metabolism. One cellular response that may mitigate these changes is mitochondrial 
biogenesis. Neuroprotection via mitochondrial biogenesis may be conferred, in part, by 
restoring levels of ATP (Maalouf, Rho et al. 2009), as well as local regulation of the 
second messenger calcium ion, which play roles in neurite outgrowth and synaptic 
plasticity (Mattson 2007).  
 3.1 Pilocarpine model of TLE 
An important criterion for an in vivo model of epilepsy is its ability to recapitulate 
the human condition in the formation of spontaneous recurring seizures. One such model 
in rats uses pilocarpine, a cholinergic agonist, at a convulsant dose to assault the brain 
and induce a prolonged seizure known as status epilepticus (SE). Following SE, the 
animals undergo a latent period of no seizure development. Despite the apparent 
quiescent phase, it is believed that there are ongoing biochemical and cellular changes 
occurring in the brain that underlie the development of chronic spontaneous seizures, the 
hallmark of epileptogenesis. For instance, brain lesions can be found in the pilocarpine 
model that mimic the observations in human patients with mesial temporal sclerosis. 
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Other morphological features associated with epilepsy include the loss of GABAergic 
interneurons in the dentate hilus, proliferation of astrocytes, activation of microglia 
indicative of an inflammatory response, and death of pyramidal neurons within the CA3 
and CA1 strata of hippocampus (McNamara, Huang et al. 2006). Although the granule 
cells of the dentate gyrus are resistant to cell death (Grooms, Opitz et al. 2000), the loss 
of their normal target cells leads to altered mossy fiber (axons of granule cells) sprouting 
into the outer molecular layer of the gyrus and reinnervating the dendrites of granule cells 
(Sutula, Cascino et al. 1989, Sarkisian 2001). These observations suggest a 
reorganization of neural networks and a contributor of hyperexcitability in epileptic 
brains. In addition to these changes in cellular connectivity, animal models suggest that 
there are key molecular responses in neurons driven by increased levels of BDNF.        
 3.2 BDNF signaling and epilepsy 
In response to seizures, BDNF expression is increased markedly (Ernfors, 
Bengzon et al. 1991, Isackson, Huntsman et al. 1991, Springer, Gwag et al. 1994) at both 
the levels of mRNA (Murray, Isackson et al. 2000) and protein (Takahashi, Hayashi et al. 
1999) in the hippocampus, particularly in the dentate gyrus and CA1-CA3 pyramidal 
cells (Binder, Croll et al. 2001). As a member of the neurotrophin family, BDNF is 
essential to neuronal survival, differentiation and long-term potentiation during 
development of the CNS. These processes are regulated by the binding of BDNF to its 
higher and lower affinity receptors, TrkB and p75NTR, respectively. Although its 
physiological function may suggest a neural protective role, genetic models seem to 
provide evidence for the role of BDNF signaling in epileptogenesis. An additional animal 
  
19 
model to pilocarpine used to study epileptogenesis is kindling, which enhances a 
neuron’s sensitivity to electrical stimulations and to the subsequent stimulation of seizure 
activity.  This model allows researchers to induce seizures using electrical stimuli for the 
animal’s lifespan. Comparing BDNF(+/+) wild type and heterozygous BDNF(+/-) knockout 
animals undergoing kindling, BDNF(+/-)  knockout animals exhibited reduced rate of 
kindling development, meaning more stimulations were required to reach the same level 
of seizure severity as the wild type animals (Kokaia, Ernfors et al. 1995). The suppressed 
epileptogenesis in the kindling model is also supported by another study where fusion 
antibodies composed of the TrkB receptor ligand-binding domain and Fc portion of 
human immunoglobulin IgG1 were introduced to compete against the actions of 
endogenous neurotropins in the hippocampus (Binder, Routbort et al. 1999). CNS 
specific elimination of either BDNF or TrkB shows that while homozygous knockout of 
BDNF had little effect on epileptogenesis, epileptogenesis was completely eliminated in 
the TrkB receptor knockout when employing the kindling model (He, Kotloski et al. 
2004). This finding implies a major role for the TrkB receptor in epileptogenesis and a 
potential role for additional TrkB ligands such as Neurotrophin 3 (NT3). In addition, 
substitution of phenylalanine for tyrosine at residue 816 in TrkB has been shown to 
disrupt the activation of phospholipase Cγ1 (PLCγ1) which inhibits limbic 
epileptogenesis (He, Pan et al. 2010).  
The molecular basis of epileptogenesis involving BDNF signaling continues to be 
an active area of research. Our laboratories (Russek and Brooks-Kayal) have identified 
BDNF signaling as a mediator of GABAR α1 subunit downregulation and GABAR α4 
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subunit upregulation that follows SE in the pilocarpine model of TLE (Brooks-Kayal, 
Shumate et al. 1998, Roberts, Hu et al. 2006, Lund, Hu et al. 2008). We reported how 
BDNF can alter the number of GABARs at the synapse and how one receptor subtype 
can be replaced with another that desensitizes rapidly (Lund, Hu et al. 2008).  A decrease 
in α1 subunit levels has also been observed in human TLE hippocampal tissues (Loup, 
Wieser et al. 2000) suggesting that altered GABAR subunit gene (GABR) transcription is 
a hallmark of the human condition. Ultimately, changes in BDNF signaling may 
chronically alter the expression of inhibitory systems, especially its function via the 
altered expression of certain GABAR subunits in target neurons, leaving the brain 
susceptible to the development of spontaneous seizures and to a subsequent decline in 
both cognitive function and emotional stability in patients. 
 3.3 GABARs and epilepsy 
There are nineteen different subunit genes, grouped into eight classes (i.e. α1-6, 
β1-3, γ1-3, δ, ε, θ, π, ρ1-3), that contribute to the diversity of GABAA receptors, and in 
turn, to the differential assembly of these subunits into receptors at the cell surface. The 
majority of the GABAA receptors are composed of two α, two β subunits and either γ2 or 
δ. The γ2 subunit is required for the clustering of GABAA receptors at the synapse 
(Essrich, Lorez et al. 1998). GABARs containing the γ2 subunit exhibit low affinity for 
GABA, but are positioned at the synapse where there is the highest concentration of 
GABA. In contrast, GABARs containing the δ subunit are commonly outside of the 
synapse (e.g. perisynaptic or extrasynaptic) and exhibit a high affinity for GABA. This is 
important as GABA diffuses away from the synapse and is much lower in concentration. 
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The GABAR is a ligand-gated Cl- ion channel that mediates inhibitory 
neurotransmission in the adult mammalian CNS. For each receptor, two molecules of 
GABA binds, one at each α and β subunit interface (Connolly and Wafford 2004, Olsen 
and Sieghart 2009). In the adult brain, GABA activation leads to anion influx, resulting in 
hyperpolarization of the cell membrane. While in the developing brain, due to the 
expression of the Na-K-Cl cotransporter (NKCC1), Cl- ions are taken up into the cell. 
This is complemented by a low to modest expression of the K-Cl co-transporter (KCC2) 
that is responsible for Cl- efflux from neurons (Rivera, Voipio et al. 1999). Ultimately, 
the net effect is the maintenance of a high intracellular Cl- concentration in the immature 
neuron. 
The subunit composition of GABARs and their cell surface localization provide a 
molecular basis for both phasic and tonic inhibition in the nervous system. In addition to 
the δ subunit, the α4 subunit plays a major role in mediating tonic inhibition. In the 
dentate granule (DG) cells of α4 knock-out mice, tonic inhibition is markedly reduced 
(Chandra, Jia et al. 2006). Pharmacologically, recombinant GABAARs containing α4 and 
α6 subunits are insensitive to modulation by benzodiazepines (Wisden, Herb et al. 1991) 
and more sensitive to zinc inhibition than those containing α1 (Knoflach, Benke et al. 
1996, Fisher and Macdonald 1998). Our laboratory discovered that α4 subunit gene 
expression is specifically under the control of BDNF via the Trk B receptor and MAPK 
signaling (Roberts, Hu et al. 2006). In animal models of TLE, α4 subunit expression is 
increased in DG after prolonged seizures (Brooks-Kayal, Shumate et al. 1998, Roberts, 
Raol et al. 2005) and SE increases the abundance of α4 subunits in γ2 containing 
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receptors in this region (Lund, Hu et al. 2008). Such subunit changes like the up-
regulation of α4 in the hippocampal formation may underlie ACD resistance as 
demonstrated in phenobarbital-resistant epileptic rats (Bethmann, Fritschy et al. 2008). 
Along with decreased α1 subunit expression, these changes in GABRA4 transcription may 
contribute greatly to alterations in neural excitability and the process of epileptogenesis.  
 3.4 β1 subunit-containing GABARs 
While the transmembrane domains of each GABAR subunit are highly conserved, 
the intracellular domains are genetically divergent, giving rise to residues for differential 
receptor regulation. These include sites for ubiquitination, palmitoylation, and 
phosphorylation (Kittler and Moss 2003, Jacob, Moss et al. 2008) that affect receptor cell 
surface expression, trafficking, and localization.  These post-translational modifications 
of GABARs ultimately determine neuronal excitability. In particular, the intracellular 
domains of the β subunits have emerged as a key component of GABAR synaptic 
expression. For cell surface expression, GABAR subunits are assembled in the ER and 
directed through the secretory pathway. Part of this process is mediated by the ubiquitin-
like protein Plic-1, a protein that links integrin-associated protein with the cytoskeleton-1, 
thereby stabilizing the receptor in the ER and inhibiting ubiquitin-mediated degradation 
(Walters, Kleijnen et al. 2002). Plic-1 interacts with both α and β GABAR subunits 
(Bedford, Kittler et al. 2001). NSF (ethylmaleimide sensitive factor) in association with 
GABARAP (GABAR-associated protein) and PRIP1/2 (phospholipase C-related 
catalytically inactive proteins 1 and 2) also bind with β subunits, as well as γ subunits, 
and control the trafficking of GABARs to the cell surface (Uji, Matsuda et al. 2002, 
  
23 
Terunuma, Jang et al. 2004, Goto, Terunuma et al. 2005, Mizokami, Kanematsu et al. 
2007).  
β subunits of GABARs show differential post-translational modification.  While 
β1 and β3 can be phosphorylated by cAMP-dependent protein kinase A (PKA), the β2 
subunit is resistant (McDonald, Amato et al. 1998). The phosphorylation state of 
GABARs determines its cell surface expression and synapse localization. The 
dephosphorylated β subunits can interact with the μ2 subunit of the AP2 protein (Clathrin 
adaptor protein 2) that internalizes GABARs as part of clathrin-mediated endocytosis, 
leading to either degradation or receptor recycling (Kittler, Chen et al. 2005, Kittler, 
Chen et al. 2008). The β subunit also participates in the receptor’s endocytic recycling via 
interacting with BIG2 (brefeldin A-inhibited GDP/GTP exchange factor 2) (Charych, Yu 
et al. 2004). Interestingly, huntingtin-associated protein 1 (HAP1) can interact with the 
cytoplasmic domains of β subunits to facilitate GABAR vesicular transport back to the 
cellular membrane (Kittler, Thomas et al. 2004).  
The human β1 subunit gene (GABRB1) is located on chromosome 4, as part of a 
GABAR gene cluster that contains α2, α4, and γ1 (McLean, Farb et al. 1995). Recently, it 
was reported that specific mutations in Gabrb1 of mice produce increased alcohol 
consumption associated with increased tonic inhibition (Anstee, Knapp et al. 2013).  
These findings suggest a role for GABRB1 in alcoholism, consistent with data from 
association studies (Parsian and Zhang 1999, Sun, Cheng et al. 1999, Zinn-Justin and 
Abel 1999, Song, Koller et al. 2003).  
Disrupted GABAR-mediated neurotransmission is implicated in various nervous 
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system disorders (Hines, Davies et al. 2012). Expression of GABRβ1 is reduced in the 
lateral cerebella of subjects with bipolar disorder, major depression, and schizophrenia 
compared to healthy controls (Fatemi, Folsom et al. 2013). Levels of β1 subunits are also 
reduced in the brains of subjects with Autism (Fatemi, Reutiman et al. 2010). In the 
Fragile X mental retardation mouse model, where the gene Fragile X mental retardation 1 
(fmr1) is removed, both β1 and β2 subunit mRNAs are reduced (D'Hulst, De Geest et al. 
2006).  
 3.5 Transcription of the β1 subunit gene 
The TATA-less GABRB1/Gabrb1 promoter (GABRB1-p/Gabrb1-p) is known to 
contain multiple transcriptional start sites within a CpG island (Ma, Song et al. 2004, 
Roberts, Raol et al. 2005) and exhibit neuronal-selective expression (Chandra, Jia et al. 
2006). In unraveling the molecular determinants of GABAR β1 subunit gene regulation, 
our laboratory has demonstrated that the minimal GABRB1-p lies within the first 500 bp 
of the 5’ flanking region. Within this region of the promoter, we have found a conserved 
initiator element (Inr) that mediates down-regulation of Gabrb1 transcription by GABA 
(Russek, Bandyopadhyay et al. 2000). Recently, we identified a role for the polycomb-
like protein, PHF1b, as a transcriptional regulator that mediates GABA-induced 
downregulation (Saha, Hu et al. 2013). In my thesis project, I identified a new regulator 
for GABRB1; and, for the first time, link its transcription to potential programs of 
cellular respiration and energy consumption. Although previously identified as important 
for the coupling of neuronal excitation to increased mitochondrial biogenesis via NRF-1, 
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my findings are the first to link the mitochondrial and nuclear genomes to the potential 
regulation of GABAergic signaling.  
C.  CREB and activity-dependent gene expression 
 
1. Post-translational modification 
 
In response to either electrical or chemical stimuli, a wave of biochemical 
changes occur in neurons that ultimately lead to the alteration of synaptic strength and 
neural excitability. A key intracellular component that these extracellular signals 
converge on is the messenger molecule cyclic adenosine monophosphate (cAMP). cAMP 
is formed from ATP by the enzyme adenylate cyclase, which is activated by specific G 
proteins that are coupled to various receptors at the membrane surface. Binding of cAMP 
liberates the catalytic subunit of the cyclic AMP-dependent protein kinase or Protein 
Kinase A (PKA), which mediates the transfer of a phosphate group from ATP to serine or 
threonine residues of its substrates. Depending on the nature of the target protein, the 
phosphorylation event can either lead to activation or inactivation of the protein, a form 
of molecular “on/off” switch. A set of PKA targeted proteins are known as transcription 
factors, which can enter the cell nucleus, bind to gene promoters, and alter transcription 
and gene expression. One such factor important to the function of the nervous system is 
the cAMP response element-binding protein (CREB).  
CREB is essential in the formation of long-term memory as mediated by the 
hippocampus and the amygdala (Montminy and Bilezikjian 1987). The relative level of 
CREB activity has also been associated with the selection of neurons for inclusion in a 
circuit that is believed to (Han, Kushner et al. 2007). As a dimer, CREB acts as a 
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transcriptional regulator by binding to the promoter region of a gene that contains the 
eight-bp canonical cAMP Response Element (CRE), 5’-TGACGTCA-3’.  The activated 
CREB recruits cofactors and components of the transcriptional machinery necessary for 
RNA synthesis. An important residue in CREB responsible for its activation is serine 133 
(S133), one of several serine residues within the regulatory domain known as kinase-
inducible domain (KID) that spans residues 123-151 (Johannessen, Delghandi et al. 2004, 
Johannessen, Delghandi et al. 2004). Once S133 is phosphorylated, CREB associates 
with one of its co-activator, the CREB-binding protein (CBP) or its paralog p300, at the 
kinase inducible interacting (KIX) domain (Chrivia, Kwok et al. 1993). In turn, CBP 
recruits the RNA polymerase II complex to the promoter for transcription initiation. 
However, the regulation of CREB is more complex. This regulatory KID domain allows 
for the convergence of a variety of kinases, including protein kinase A (PKA), calcium-
calmodulin-dependent kinases (CaMKs), and Ras/ MAPK, to regulate CREB’s function 
via post-translational modification.  
In addition to cAMP and PKA signaling, CREB activation can be induced in 
response to increased intracellular Ca2+ (West, Griffith et al. 2002). Typically, 
intracellular homeostatic Ca2+ concentration is kept at low levels. Ca2+ influx can occur 
through the opening of ligand-gated ionotropic glutamate receptors, such as NMDA 
receptors during glutaminergic transmission, and voltage-gated Ca2+ channels (VDCCs), 
particularly the L-type Ca2+ channel. Ca2+ interacts with calmodulin (CaM), a calcium 
sensor, which acts to activate Ca2+-CaM kinases (e.g. CaMKI, CaMKII, and CaMKIV). 
In vitro, these CaMKs can phosphorylate CREB (Dash, Karl et al. 1991, Sheng, 
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Thompson et al. 1991, Enslen, Sun et al. 1994, Matthews, Guthrie et al. 1994, Sun, 
Enslen et al. 1994, Bito, Deisseroth et al. 1996, Kornhauser, Cowan et al. 2002, West, 
Griffith et al. 2002). The most notable and well-characterized of these is CaMKIV, which 
phosphorylates CREB S133 in vivo (Ho, Liauw et al. 2000, Ribar, Rodriguiz et al. 2000, 
Kang, Sun et al. 2001, Anderson and Means 2002, Wei, Qiu et al. 2002, Wei, Qiu et al. 
2002). Evidence for CaMKIV regulation of CREB is supported by over-expression 
studies where constitutively active CaMKIV drives CREB-dependent gene expression 
(Enslen, Sun et al. 1994, Matthews, Guthrie et al. 1994, Sun, Enslen et al. 1994). These 
results are complemented by additional evidence from animal models where CaMKIV 
inhibition and CaMKIV deficiency display a loss in CREB phosphorylation and 
decreased CREB-targeted gene expression (Bito, Deisseroth et al. 1996, Ho, Liauw et al. 
2000). In addition, it has been shown that Ca2+-CaM kinase signaling, in part, accounts 
for the induction of CREB S133 phosphorylation in neurons as a response to stimulation 
by the neurotrophin brain derived factor (BDNF) in hippocampal slices. In fact, it has 
been suggested that CREB plays a key role in mediating gene expression in responses to 
neurotrophins (Finkbeiner, Tavazoie et al. 1997). 
CaMK phosphorylation does not always lead to CREB activation. For instance, 
CaMKII can also phosphorylate CREB on residue Serine 142 (S142) in vitro, which 
disrupts CREB dimerization and CREB-CBP interactions without affecting DNA binding 
capacity (Radhakrishnan, Perez-Alvarado et al. 1997, Parker, Jhala et al. 1998, Wu and 
McMurray 2001). Thereby, inactivating transcription of CRE-dependent genes. Despite 
these findings, S142 phosphorylation cannot be generalized as a marker of CREB 
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inactivation because S142 phosphorylation has also been linked to active CREB mediated 
transcription (Gau, Lemberger et al. 2002, Kornhauser, Cowan et al. 2002). Together, 
these observations point to the possibility that CREB-dependent gene expression is more 
complicated than originally described and may even take place irrespective of CBP 
interactions (Lonze and Ginty 2002).  
In addition to BDNF, activation of growth factor signaling and receptor tyrosine 
kinase (RTK) results in the phosphorylation of CREB at S133. First, stimulation by the 
neurotrophin, nerve growth factor (NGF), activates its Trk A receptor, an RTK that 
activates Ras and stimulates the serine/threonine kinase, Raf, that then activates MEK as 
part of a sequence of kinase cascades (Raf-MEK-ERK-RSK). The activated ERKs and 
RSKs then phosphorylate CREB at S133 (Xing, Ginty et al. 1996) (Finkbeiner, Tavazoie 
et al. 1997). In contrast to the Ca2+-CaM-CaMKIV pathway, this Ras-ERK-RSK2 
pathway results in slow phosphorylation kinetics instead of the rapid 
phosphorylation/dephosphorylation that is a function of S133 regulation. Therefore, the 
effect of phosphorylation on CREB may be achieved by diverse mechanisms, in a 
pathway and cell-type dependent manner. The complexity of CREB signaling and its 
importance to processes of cognition argues that it will be critical to develop molecular 
tools in the future that can be used to dissect out the distinct molecular signatures 
associated with different aspects of CREB-mediated brain function, an area of focus in 
the research of my thesis.  
2. Models for CREB-mediated gene regulation 
The prevailing model for CREB-dependent gene regulation is that CREB binds 
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constitutively to the cAMP-response element (CRE) within promoters in its inactive form 
(i.e. not phosphorylated at S133). Upon stimulation of intracellular signaling, CREB is 
phosphorylated on the DNA, facilitating transcriptional activation, with gene expression 
increasing several fold (Barco, Lopez de Armentia et al. 2008). However, through 
chromatin immunoprecipitation (ChIP) analysis using genomic extracts from 
unstimulated cultured cortical neurons, the Ginty group found little to no binding of 
CREB in promoters with known functional CREs. Their findings, taken together with our 
own (Lau, Saha et al. 2004), suggest that CREB may be recruited to the DNA in an 
activity-dependent manner.  
 CREB is part of a larger family of transcription factors that possess a highly 
similar basic region/leucine zipper (bZIP) domain, which recognize CREs. This family 
includes a subcategory of related factors CREM (cAMP response element modulator) and 
ATF-1 (activating transcription factor 1). The basic region alpha helices contact the 
major groove of DNA, interacting with the DNA backbone at phosphates. Results of 
mutagenesis studies show that leucine residues are required for dimerization. . Homology 
zipper DNA-binding domain in the C-terminus of transcription factors classifies them as 
a member of the CREB/Activating Transcription Factor (ATF) family. Two glutamine-
rich regions Q1 and Q2 flank the KID domain. These regions help to anchor CREB to 
CRE-containing promoters and facilitate its interactions with the transcriptional 
machinery. CREB can homodimerize or heterodimerize with its family-members that 
contain leucine zippers, ATF-1 or cAMP responsive element modulator (CREM).   
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3. Potential mechanisms in the attenuation of CREB signaling  
The inducible cAMP early repressor (ICER) is a gene product transcribed from 
the intronic region of the CREM gene via promoter P2 (Molina, Foulkes et al. 1993). 
Unlike CREM, ICER contains both, or the second DNA binding domain of CREM, but 
lacks the transactivating domain that is responsible for CREM’s function as a 
transcriptional activator.  ICER can form homodimer and heterodimers with all other 
CREM and CREB proteins, but homodimer formation is more favorable (Molina, 
Foulkes et al. 1993, Stehle, Foulkes et al. 1993). As a homodimer, ICER can bind to the 
CRE, but since it lacks a transactivation domain, it represses the transcription of CRE 
containing genes by competing for interaction with the coactivator proteins CBP or 
TFIID, or both (Sun and Maurer 1995, Nakajima, Uchida et al. 1997). Support for ICER 
as a repressor of CREM mediated transcription comes from studies of ICER IIγ 
overexpression where forskolin-induced CRE-driven transcription is blocked (Burkart, 
Mukherjee et al. 2006, Misund, Steigedal et al. 2007, Steigedal, Bruland et al. 2007). 
ICER splice variants have also been shown to exert cell-type specific effects on cell 
growth (Razavi, Ramos et al. 1998, Memin, Yehia et al. 2002, Misund, Steigedal et al. 
2007). In summary, ICER, like CREB, is critical for diverse activity-dependent 
processes; and, in fact, there may be a critical balance between CREB and ICER genomic 
programs that underlies brain plasticity and its associated functional disorders. 
 As a goal of my thesis work, I developed a novel reporter system to study the 
effects of ICER expression on CREB/CBP interactions that can be used in the future to 
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monitor the presence of ICER in response to chronic exposure to neurotrophins, like 
BDNF whose levels rise dramatically upon status epilepticus (See Chapter 4).  
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CHAPTER II: MATERIALS AND METHODS 
 
A. Cell culture 
Human embryonic kidney (HEK) cell culture 
HEK cells were grown in Dulbecco’s Modified Eagle Medium containing 4.5g/L D-
Glucose and 4mM L-Glutamine, supplemented with 0.1mM non-essential medium and 
10% fetal bovine serum. Cells were cultured in an incubator that maintained the cells at 
37ºC and 5% CO2. Cells were detached with 0.25% (w/v) Trypsin-0.53mM EDTA 
solution and subcultivated at ratio of 1:20 every 3-4 days in 75 cm2 flask.   
Primary neuronal cell culture 
Primary hippocampal and neocortical neurons are isolated from embryonic day 18 
Sprague-Dawley rat embryos (Charles River Laboratories). Isolated embryonic brains 
and the subsequently dissected hippocampi cortices were maintained in ice-cold modified 
calcium-magnesium free Hank’s Balanced Salt Solution (HBSS) (4.2mM sodium 
bicarbonate, 1 mM sodium pyruvate, and 20 mM HEPES, 3mg/ml BSA) buffering 
between pH range 7.25 – 7.3. Tissues are then separated from HBSS dissection solution 
and trypsinized (0.05% trypsin-EDTA) for 10 minutes in 37ºC and 5% CO2. The trypsin 
reaction is stopped with serum inactivation using Neural Basal Medium (NBM) 
containing plating medium (10% FBS, 10 U/ml penicillin/streptomycin, 2mM L-
glutamine). Tissues are titrated with 1000 mL micropipette and diluted to a concentration 
of 0.5x106 cells/mL in plating media for plating. Cells are allowed to adhere onto Poly-L-
lysine coated culturing surface for 1 h prior to changing to serum-free feeding medium 
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(2% B-27, 2mM glutamine, 10 U/ml penicillin/streptomycin supplemented NBM). 
Neuronal cultures are maintained in 37ºC and 5% CO2 incubator. 
B. Chromatin immunoprecipitation (ChIP) 
ChIP is performed according to Magna ChIP A protocol (Millipore). Briefly, primary 
neurons in 100 mm dishes are fixed with final concentration of 1% formaldehyde in 
culturing medium. The remaining unreacted formaldehyde is quenched with Glycine. 
Genomic DNA and protein complex are extracted from cells using nuclear lysis buffers 
supplemented with protease and phosphatase inhibitors. The lysates containing DNA-
protein complexes are sonicated (nine times, 5 minutes each at a 30s on/off interval) in an 
ice-cold water bath with Bioruptor (Diagenode) in order to generate fragments 
predominantly in the range of 200 – 1000 bp in size. The sheared chromatin is 
immunoprecipitated with either anti-NRF-1 antibody (Abcam ab34682 ChIP grade 
antibody) or normal rabbit IgG overnight at 4 OC with constant rotation. The 
antibody/transcription factor bounded chromatin is separated from unbound chromatin 
using Protein A conjugated magnetic beads and magnetic pull-down. The isolated 
complexes are washed with a series of salt buffer solutions prior to eluting and reverse 
cross-linking DNA from complexes using NaCl, EDTA, Proteinase K and heating. DNA 
fragments are recovered through column purification. The immunoprecipitated DNA 
fragments are identified by quantitative PCR (qPCR) using specific primer and TaqMan 
probe that flank putative responsive elements in gene promoters. qPCR was performed 
using the ABI7900HT real-time PCR system and FastStart Universal Probe Master mix 
(Roche) in 20 μl reactions.  
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C. Electrophoretic mobility shift (EMSA) and supershift assay. 
Briefly, ~30 bp DNA probes containing putative NRF-1 binding sequence were incubated 
with 25µg of neocortical nuclear extracts for electrophoresis under non-denaturing 
conditions. Following electrophoresis, the protein-DNA complexes were detected by 
exposing the gel to x-ray film (Kodak) as part of autoradiography. The DNA probes were 
created from annealing synthesized oligonucleotides (www.idtdna.com) and 5’ end 
labeling using [γ-³²P] ATP (PerkinElmer) in a T4 polynucleotide kinase (NEB) reaction. 
Nuclear extracts were prepared from DIV 7-9 primary neocortical neurons grown on 10-
cm plates. Protein-DNA binding specificity were determined by adding poly (dI-dC) 
(Roche) or/and 100-fold excess unlabeled DNA probe prior to the addition of labeled 
probe during the binding reaction. To generate a supershift complex, NRF-1 antibody 
(AbCam) was added to the reaction mixture for 15 min to loading onto gel. The binding 
reactions were loaded onto 5% polyacrylamide gel in 0.5X TBE buffer and ran at 200V 
for 2 h at 4ºC. The positive control probe consisted of sequence from the Rat cytochrome 
c with NRF-1 binding site previously described (Evans and Scarpulla, 1990).  
Table 1. EMSA probes and competitor oligonucleotide sequences 
GABRB1 NRF1 5’-agcgcgcTCTGCGCATGCGCAggtccattc-3’ 
5'-gaatggaccTGCGCATGCGCAGAgcgcgct-3' 
GABRB1 NRF1 mutant 5’-agcgcgcTCTGCcCATGgGCAggtccattc -3’ 
5'-gaatggaccTGCcCATGgGCAGAgcgcgct-3' 
rCycs NRF1 5’-ctgctaGCCCGCATGCGCgcgcacctta-3’ 
5’-taaggtgcgcGCGCATGCGGGCtagcag-3’. 
 
D. Preparation of nuclear protein extracts. 
Cortical nuclear extracts were isolated from 4-5 100 mmm DIV 7-9 primary E18 
neocortical neurons. Lysis ‘Buffer A’ (salts and a cocktail of protease inhibitors which 
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includes DDT, PMSF, aprotinin, leupeptin and pepstatin) was used to disrupt the plasma 
membrane and protect proteins (e.g. transcription factors) from enzymatic degradation. 
The lysis reaction was incubated on ice for 15 minutes. Following incubation, 25μl of 
10% NP40 was added to each extract sample, and briefly vortexed. The resulting nuclei 
were pelleted by centrifugation at 12,000 rpm for 2 minutes at 4ºC. Once the supernatant 
is removed, the nuclei pellet was resuspended in 100-120μl of hypotonic solution ‘Buffer 
C’, breaking down the nuclear envelope, while protecting nuclear proteins from 
degradation. Mixing of buffer C and cellular extract should be done with care, only use 
pipette tip to swirl pellet in buffer. Incubate samples on a rocking platform for 1 hr at 
4ºC. Nuclear debris is separated from nuclear proteins by centrifugation (12,000 rpm for 
5 minutes at 4ºC). The subsequent supernatant, containing nuclear proteins, was collected 
and stored as 20% glycerol mixture in -80ºC freezer. 
E. Molecular cloning 
 
Subcloning promoter reporter constructs 
The minimal GABRA4p-Luc (pGL2-GABRA4) containing the first 500 bp of the 5’ 
flanking region have been previously described (Roberts et al., PNAS 2006). A 367 bp 
fragment extending from +62 to -307 with respect to the transcription start site of the rat 
cytochrome c gene (Cycs) was amplified from total rat genomic DNA (Clontech 
Laboratories, Mountain View, CA) using Phusion High-Fidelity polymerase (NEB, 
Ipswich, MA) and directionally cloned into pGL2-basic vector (Promega, Madison, WI) 
using restriction sites Kpn I and Xho I. The GABRB1p-Luc (pGL2-GABRB1) containing 
the 5’ flanking region had been previously described (Russek SJ et al., PNAS 2000). The 
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promoter containing a mutated NRF-1 element within the GABRB1p-Luc was created by 
PCR-driven overlap extension. Using wild type GABRB1p-Luc as PCR template, two 
PCR fragments were amplified using GL1 primer (Promega) and the antisense mutant 
NRF-1 oligonucleotide from EMSA, and sense mutant NRF-1 oligonucleotide and GL2 
primer (Promega), resulting in fragments with 30 bp overlapping sequences that contain 
the mutant NRF-1 element. A second PCR step using GL1, GL2 primers and both initial 
PCR products produced the mutant GABRB1 promoter insert. 
Construction of dominant-negative (DN) NRF-1.  
The pcDNA3.0-NRF-1 DN expresses amino acid residues 1-304 of NRF-1, which 
encodes the DNA-binding, dimerization and nuclear localization domains of NRF-1, but 
not the transactivation domain (amino acids 305-503). The construct was created using 
PCR with the forward primer 5’-CGGGGTACCACCATGGAGGAACACGGAGTGA 
CCCAAAC-3’, containing the underlined Kpn I restriction site and the kozak sequence 
(ACC) on the 5’ end, and the reverse primer 5’GCTCTAGATCACTGTGATGGTACA 
AGATGAGCTATACTATGTGTGGCTGTGGC-3’, containing stop codon (TGA) and 
Xba I restriction site. PCR products were digested with restriction enzymes Kpn I and 
Xba I, and ligated into pcDNA3.0 vector (Invitrogen) with T4 DNA Ligase (NEB, 
Ipswich, MA). Constructs were amplified by transforming ligation products into 
subcloning efficiency DH5α Competent cells (Life Technologies, CA). 
Split-complement luciferase constructs  
The design of the split luciferase proteins, KID-LucC and KIX-LucC were previously 
described and tested in HEK293 cells (Ishimoto T. et al., 2012). The plasmids that encode 
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these recombinant proteins were constructed (generated by Zhuting Li and Sabita 
Bandyopadhyay) using In-Fusion HD Cloning Kit (Clontech) in accordance with 
manufacturer’s directions. For each construct, five DNA fragments (i.e. two PCR-
amplified, two annealed oligonucleotides, and EcoRI and NotI linearized pCAG-Cre 
vector) were engineered to contain a 15 bp overlap that directionally fuses the fragments 
at their ends. The synthetic amino-terminal fragment contains an overlapping sequence 
with vector, the Kozak consensus sequence, and nucleotides encoding the start codon and 
nuclear localization signal (NLS) DPKKKRKVDPKKKRKV. The internal fragment, 
containing either KID of CREB (gift of ME Greenberg) or N-terminus of Luciferase 
(LucN) from the pGL2-basic vector (Promega), was PCR-amplified with 5’-end primers 
overlapping with the NLS DNA sequence. The poly GGGGS linker was synthesized with 
an overlap with either the 3’ end of KID or LucN at the 5’ end. The carboxyl-terminal 
fragment, containing either the C-terminus of Luciferase (LucC) from the pGL2-basic 
vector or KIX (total rat cDNA), were PCR-amplified with primers overlapping the 
sequence with the polyGGGGS linker at the 5’ end and linearized pCAG-Cre vector at 
the 3’ end. S133A-KID-LucC was created by PCR site-directed mutagenesis by changing 
a single nucleotide from TCC to GCC. 
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Table 2. Primers for PCR amplification of split-complement luciferase fragments 
pCAG KID-LucC Primer Sequences 
KID Fragment F: 5’-AAG AAG AGG AAG GTC CAG ATT TCA ACT ATT GCA    
GAA AGT G-3’ 
R: 5’-AGT CTC CTC TTC TGA CTT TTC-3’ 
LucC Fragment F: 5’-GGT GGA GGT GGA AGT GGA TGG CTA CAT TCT GGA 
GAC ATA GC-3’ 
R: 5’- CT GAG GAG TGC GGC CGC CAA TTT GGA CTT TCC 
GCC CTT C-3’ 
pCAG KIX-LucN  
KIX Fragment F: 5’-GGT GGC GGC GGA TCT GGT GTT CGA AAA GGC 
TGG-3’ 
R: 5’ CT GAG GAG TGC GGC CGC TCA TTC TTC TAG TTC 
TTT TTG TAT TTT ATA GAT TTT-3’ 
LucN Fragment F: 5’-AAG AAG AGG AAG GTC ATG GAA GAC GCC AAA 
AAC-3’ 
R: 5'- ATC CTT GTC AAT CAA GGC GT -3' 
 
 
Table 3. DNA sequence of split-complement luciferase fragments 
 
 
F. DNA Sequencing 
All recombinant DNA constructs were verified with sequencing performed by 
GENEWIZ, Inc. (South Plainfield, NJ) using specific forward and reverse primers (Table 
4). 
 
 
Kozak Sequence + 
Start Codon + NLS 
T TTT GGC AAA GAA TTC GAC CCG AAG AAG AAG 
AGG AAG GTC GAC CCG AAG AAG AAG AGG AAG GTC 
  
KID overlapping 
polyGGGS linker 
TCA GAA GAG GAG ACT GGT GGC GGT GGC TCG GGC 
GGT GGT GGG TCG GGT GGC GGC GGA TCT 
  
LucN overlapping 
polyGGGS linker 
TTG ATT GAC AAG GAT GGT GGC GGT GGC TCG GGC 
GGT GGT GGG TCG GGT GGC GGC GGA TCT 
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Table 4. Vector sequencing primers  
Vectors Primer Sequences 
pcDNA3.0/pcDNA3.1 T7: 5’-TAA TAC GAC TCA CTA TAG GG-3’ 
SP6: 5’-GAT TTA GGT GAC ACT ATA G-3’ 
pGL2 GLprimer1: 5’- ATG TAT CTT ATG GTA CTG TAA CTG 
GLprimer2: 5'- CTT TAT GTT TTT GGC GTC TTC CAT -3' 
pCAG F69: 5’-GTG TGA CCG GCG GCT CTA -3’ 
R1879: 5’- AGA TCT CAG TGG TAT TTG TGA GCC -3’ 
 
G. Transfection for transient mammalian cell expression. 
Calcium phosphate-mediated transfection 
Calcium phosphate mediated transfection of DNA into primary neuron cultures was 
previously described by Dudek H et al., 2001. For each well of a 6-well plate, 4-8 μg of 
DNA was transfected in 80 μl volume. In one sterile tube, DNA and one-tenth volume of 
CaCl2 were diluted in nuclease-free water to 40 μl volume. In the other sterile tube, 40 μl 
of 2X Hepes Buffer Saline (HBS) was allocated. While gently vortexing 2X HBS, the 
diluted DNA and CaCl2 solution was slowly added to the 2X HBS in a dropwise manner. 
The DNA precipitates were allowed to form at room temperature in the dark for 20 
minutes prior to transfection, primary neurons were washed with pre-warmed DMEM 
(minus glutamine) and subsequently incubated in DMEM. The formed DNA precipitates 
were added to neurons in DMEM and allowed to incubate on cells for 30-45 min at 37ºC 
and 5% CO2. Neurons were returned to feeding media after washed twice with DMEM. 
24 h after transfection, neurons were typically assayed for luciferase activity.  
Magnetofection™ with NeuroMag reagent. 
The day prior to transfection, half of the culture media was replaced with fresh feeding 
media on cells to be transfected. For each well of a 6-well plate, 2-4 μg of DNA was 
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transfected with NeuroMag reagent at a 1:1 DNA to NeuroMag reagent ratio. First, DNA 
was diluted in 200 μl of NBM in a microcentrifuge tube, and the NeuroMag reagent was 
set aside. The diluted DNA was then gently mixed into the tube of NeuroMag reagent, 
and DNA-NeuroMag complexes were allowed to form for 20 minutes at room 
temperature. The newly formed complexes were distributed onto neurons and allowed to 
incubate for 20 minutes on a magnetic plate at 37ºC and 5% CO2. After 24 h, neurons 
were evaluated for transgene expression in downstream assays.  
Lipofection-mediated transfection. 
The day before transfection, HEK 293 cells were seeded at 6.25x106 cells per well. Prior 
to transfection, all reagents were allowed to warm to room temperature. For the screening 
of active NRF-1 targeting shRNAs, each well was transfected with 0.5μg of pcDNA3 
NRF-1 and 1.0 μg of pSilencer NRF-1 shRNA, or non-targeting control. 4.5μl of X-
tremeGene 9 DNA transfection reagent (Roche) was diluted in 150 μl of Opti-MEM 
serum-free medium for 3:1 ratio using a sterile tube. After gentle mixing, DNA was 
added to the 150 μl of diluted transfection reagent and allowed to incubate for 30 min at 
room temperature. The formed reagent:DNA complex was then added to the cells in a 
dropwise fashion. After 48 h incubation, cell extracts were harvested for protein 
expression.  
H. Promoter luciferase reporter assays 
E18 primary cortical neurons (1 X 106 cells) were plated into each well of a 6-well plate 
(NUNC). On DIV7, neurons were transfected with 1μg of expression construct, 2μg of 
promoter reporter construct, and 3μl of NeuroMag transfection reagent (1:1 DNA to 
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reagent ratio). Twenty-four hours after transfection, neurons were actively lysed by 
scraping. Cell lysates were cleared of precipitates by centrifugation and then assayed for 
luciferase activity by adding Luciferase Assay Substrate (Promega). Luciferase reporter 
activity was measured by using the GloMax Multi-Detection system luminometer 
(Promega). Luciferase activity was normalized to total protein as determined by 
Coomassie protein assay (Thermo Scientific Pierce). All transfections were performed in 
duplicates and using three or more platings of neurons, each from an individual animal. 
I. Assays for protein determination 
Bradford protein assay  
A total protein quantification method was employed that uses a dye-based bio-rad protein 
assay (Bio-Rad #500-0006) and an albumin based standard curve to quantify protein 
extracts. Standard curve proteins were prepared using a 1mg/ml stock of Bovine Serum 
Albumin (BSA) to create standards with known amounts 0, 1, 2, 4, 8, and 16 μg of BSA. 
The background/baseline solution contained 4 μl of lysis buffer (e.g. 1X RIPA) and the 
remaining volume was made up of water for a total volume of 800μl. Four μl of unknown 
protein sample was diluted with 796 μl of water for a 1:250 dilution. To all samples and 
standards, 200 μl of Bio-Rad Protein Assay Dye was added and samples were vortexed. 
The mixture was then incubated in room temperature for about 20 minutes (or until there 
was an appropriate color change) prior to reading samples using a spectrophotometer at 
absorbance at 600 nm GloMax (Promega). Protein concentrations and absorbance 
readings were positively correlated and linear within the given concentration range. 
Coomassie protein assay 
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A total protein quantification method that uses a Coomassie assay dye (Thermo 
Scientific) and an albumin based standard curve was used to quantify protein extracts in 
Passive Lysis Buffer (Promega). The known standards (2000, 1500, 1000, 750, 500, 250, 
125, 25 μg/ml of BSA) were prepared using a 2mg/ml BSA stock. The 
background/baseline solution contained lysis buffer (e.g. 1X Passive Lysis Buffer) and 
the remaining volume was made up of water for a total volume of 800μl. Four μl of an 
unknown protein sample was diluted with 796 μl of water for a 1:250 dilution. To all 
samples and standards, add 300 μl of Coomaissie Protein Assay Dye and vortex samples. 
Allow the mixture to incubate in room temperature for about 20 minutes prior to reading 
samples using a spectrophotometer absorbance at 600 nm GloMax (Promega). Protein 
concentrations and absorbance values (595 nm) were positively correlated and related by 
second-order polynomial. 
J. Quantitative reverse-transcription PCR (qRT-PCR)  
Total RNA was isolated from cultured primary neocortical or hippocampal neurons using 
RNeasy Micro Kit (Qiagen) according to manufacturer’s protocol. RNA concentration 
was determined by Nanodrop (Thermo Scientific) spectrophotometer at 260 nm 
absorbance. For each qRT-PCR, 20-100 ng of total RNA was reverse-transcribed to 
cDNA, and PCR amplified in a single reaction mixture using TaqMan® One-Step RT-
PCR Master Mix Reagents Kit (Applied Biosystems), and target specific TaqMan probe 
and primer set. Incubation and thermal cycling conditions were performed using the 
ABI7900HT in the 384-well PCR plate format (Applied Biosystems). RT reaction was 
held at 48ºC for 30 min, followed by 95ºC for 10 min for polymerase activation.  PCR 
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was then performed with 15 sec denaturation at 95ºC, annealing and extension for 1 min 
at 60OC for 40 cycles. Rat cyclophilin A gene expression served as internal control. 
Relative gene expression was quantified using ΔΔCT and standard curve generated based 
on amplification of total RNA extracted from untreated cultured neurons. 
K. RNA interference 
The pSilencer™ siRNA expression vector system was used to express NRF-
1 specific hairpin siRNAs under control of the human U6 RNA pol III promoter 
(pSilencer 2.0-U6, Life Technologies).  Four hairpin siRNAs were constructed with a 
common hairpin loop sequence (TTCAAGAGA), RNA Polymerase III terminator 
sequence (TTTTTT), and 19 complementary nucleotide sequences targeting the 
coding region of NRF-1. siRNA sequences were selected and validated as previously 
described (Dhar S.S. and Won-Riley, M.T.T., 2009). Directional cloning of the siRNA 
templates into the pSilencer vector was facilitated using BamH1 (G^GATC_C) and 
HindIII (A^AGCT_T) restriction sites. A negative control vector expressing a non-
targeting siRNA (5’-ACTACCGTTGTTATAGGTG-3’) that lacks significant homology 
to the human and murine genomes, as validated by the manufacturer, was used as a 
control in our silencing assays.  
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Table 5. Sequences encoding NRF-1-targeting shRNAs  
Name Sequences 
NRF-1 shRNA #6 GATCCGAAAGCTGCAAGCCTATCTTTCAAGAGAAGATAG
GCTTGCAGCTTTCTTTTTTGGAAA 
NRF-1 shRNA #7 GATCCGCCACAGGAGGTTAATTCATTCAAGAGATGAATT
AACCTCCTGTGGCTTTTTTGGAAA 
NRF-1 shRNA #8 GATCCGCATTACGGACCATAGTTATTCAAGAGATAACTA
TGGTCCGTAATGCTTTTTTGGAAA 
NRF-1 shRNA #9 GATCCAGAGCATGATCCTGGAAGATTCAAGAGATCTTCC
AGGATCATGCTCTTTTTTGGAAA 
NRF-1 shRNA #10 GATCCGGGCAACAGTAGCCACATTTTCAAGAGAAATGTG
GCTACTGTTGCCCTTTTTTGGAAA  
 
L. Western blot analysis 
Total proteins were extracted from cells using RIPA lysis buffer (Tris, pH 7.4, 10 mM; 
Nonidet P-40 1%; NaCl 150 mM; SDS 0.1%) supplemented with protease and 
phosphatase inhibitors (Roche Applied Science), EDTA 1mM; sodium orthovanadate 1 
mM; sodium deoxycholate 0.1%; phenylmethylsulfonyl fluoride 1 mM. 20-30 μg of 
whole cell extracts were separated by SDS-PAGE under reducing conditions on either 
10% or 4-20% Tris-glycine gel according to mass/size. The electrophoresed samples 
were transferred to nitrocellulose membrane for detection. The membrane was probed for 
proteins of interest using primarily rabbit polyclonal antibodies and peroxidase-
conjugated goat anti-rabbit secondary antibody (1:5000 dilution in 1X TBS-T). Proteins 
were detected with enhanced chemiluminescence reagent (ECL) (GE Healthcare Life 
Sciences) and visualized on x-ray film (Thermo Scientific). Immunoblot films were 
scanned and protein band intensities were quantified using ImageQuant™ TL software 
(GE). Levels of β-actin (mouse monoclonal Anti-β-actin Ab) were used to normalize 
whole cell/cytoplasmic protein extracts.  
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M. Bioluminescence Imaging 
In vivo imaging system 
Primary cortical neurons (5 x 104 per well of 96-well black-walled plate) were transiently 
transfected with plasmids using the NeuroMag (Oz Biosciences) protocol at DIV 8. To 
image live cells, the D-luciferin substrate (20 µl of 1.5 mg/ml in Calcium and Magnesium 
free 1X PBS) was added to wells containing 200 µl of media. Nine to 10 min were given 
for cellular uptake of the membrane permeant D-luciferin prior to imaging. Photon flux 
for each well was measured with an IVIS charge-coupled device camera (1 or 4 min 
exposure). 
Bioluminescence microscope imaging system 
Primary cortical neurons (1 x 106 per 35mm confocal dish) were transiently transfected 
with plasmids (NeuroMag (Oz Biosciences)) described above at DIV 8. To image 
individual live neurons, D-luciferin (20 µl of 1.5 mg/ml in Calcium and Magnesium free 
1X PBS) was added to wells containing 200 µl of media. Cells were given 9-10 min for 
D-luciferin uptake prior to imaging. Live cell images were acquired using the Olympus 
LV200 Bioluminescence Imaging System, where neurons were maintained in an 
incubation chamber kept at 37ºC and 5% CO2. 
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CHAPTER III. A role for nuclear respiratory factor 1 (NRF-1) in the control of β1-
containing GABARs  
 
A. Abstract 
The physiological role of β1 subunit-containing type A GABA receptors 
(GABARs) has not been well characterized, although altered expression of β1 is 
associated with neurological and neuropsychiatric disorders. In particular, down-
regulation of β1 subunit levels is observed in the brains of patients with epilepsy, autism, 
bipolar disorder, and schizophrenia. A pathophysiological feature of these disease states 
is an imbalance in energy metabolism and mitochondrial dysfunction. The transcription 
factor, nuclear respiratory factor 1 (NRF-1), has been shown to be a key mediator of 
genes involved in oxidative phosphorylation, mitochondrial biogenesis and synaptic 
transmission. Using a variety of molecular approaches (including mobility shift, 
promoter/reporter luciferase assays, and RNA silencing), we now report that NRF-1 
regulates the transcription of the GABAR β1 subunit gene (GABRB1) in neurons and that 
its core promoter region contains a conserved canonical NRF-1 element responsible for 
sequence specific binding and transcriptional control over expression. Our identification 
of GABRB1 as a new target for NRF-1 suggests that the genes coding for inhibitory 
neurotransmission, in addition to excitatory, may be coupled to cellular metabolism. 
B. Introduction 
The type A γ-aminobutyric acid receptor (GABAR) is a ligand-gated Cl- ion 
channel that mediates inhibitory neurotransmission in the adult mammalian central 
nervous system. The majority of GABARs are composed of two α and two β subunits, 
and either a γ2 or δ subunit (Farrar, Whiting et al. 1999, Barrera, Betts et al. 2008, Patel, 
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Mortensen et al. 2014). For each receptor, there is the binding of two molecules of 
GABA, one molecule at each α and β subunit interface (Rabow, Russek et al. 1995, 
Connolly and Wafford 2004, Olsen and Sieghart 2009). In the mature neuron, activation 
of GABARs leads to hyperpolarization. Depending on its subunit composition, GABARs 
may contain binding sites for barbiturates, benzodiazepines, ethanol, and/or neuroactive 
steroids. There are nineteen different subunit genes to date, grouped into eight classes 
(i.e. α1-6, β1-3, γ1-3, δ, ε, θ, π, ρ1-3) that contribute to the diversity and differential 
assembly of receptor subtypes. The β subunits, which contain the domains that interact 
with mediators of receptor trafficking and endocytosis (for reviews see (Jacob, Moss et 
al. 2008, Vithlani, Terunuma et al. 2011)), play an important role in the expression of 
GABARs at the cell surface.  
The human GABRB1 gene, located on chromosome 4, is part of a GABAR gene 
cluster that contains the genes that encode the α2, α4, and γ1 subunits. A dysregulation of 
GABAR-mediated neurotransmission has been implicated in various neurological 
disorders (Hines, Davies et al. 2012) that show altered levels of GABAR subunits, 
including β1. Through linkage studies, GABRB1 has been associated with alcohol 
dependence (Parsian and Zhang 1999, Sun, Cheng et al. 1999, Zinn-Justin and Abel 
1999, Song, Koller et al. 2003); and recently, it was reported that specific mutations in 
mouse Gabrb1 produce increased alcohol consumption that is linked to increased tonic 
inhibition (Anstee, Knapp et al. 2013).  
GABRB1 expression is also reduced in the lateral cerebella of subjects with 
bipolar disorder, major depression, and schizophrenia compared to healthy subjects 
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(Fatemi, Folsom et al. 2013). Particularly in schizophrenia, a significant association of 
GABRB1 has been identified by genome-wide association studies that were coupled to a 
protein-interaction-network-based analysis (Yu, Bi et al. 2014). As GABRB1 and 
GABRA4 lie within the same GABAR gene cluster, it is interesting to note that GABRA4 
association with the risk of developing autism increases with a GABRB1 interaction (Ma, 
Whitehead et al. 2005, Collins, Ma et al. 2006), suggesting that these genes may be 
coordinately regulated. Further evidence for a GABRB1 association with autism is seen in 
the decreased levels of β1 subunit protein within the brains of autistic subjects (Fatemi, 
Reutiman et al. 2009, Fatemi, Reutiman et al. 2010). In addition, the levels of both β1 
and β2 subunit mRNAs are reduced in a Fragile X mental retardation mouse model, 
where the gene Fragile X mental retardation 1 (fmr1) was removed (D'Hulst, De Geest et 
al. 2006). Finally, down-regulation of β1 subunit mRNAs and protein are observed in the 
rat pilocarpine-model of epilepsy (Brooks-Kayal, Shumate et al. 1998). Yet, despite its 
prevalent association with neurological disorders, there is still little known about the 
function and/or regulation of β1 in neurons. 
The TATA-less GABRB1/Gabrb1 promoter (GABRB1-p (human)/Gabrb1-p 
(rodent)) contains multiple transcriptional start sites that lie within a CpG island (Russek, 
Bandyopadhyay et al. 2000, Saha, Hu et al. 2013). In unraveling the molecular 
determinants of GABAR β1 subunit gene regulation, our laboratory demonstrated that the 
minimal GABRB1-p lies within the first 500 bp of the 5’ flanking region. Within this 
region there is a conserved initiator element (Inr) that mediates down-regulation in 
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response to chronic GABA exposure, implicating an autologous mechanism of 
transcriptional control (Russek, Bandyopadhyay et al. 2000, Saha, Hu et al. 2013).   
Nuclear respiratory factor 1 (NRF-1) is a transcription factor that functions 
primarily as a positive regulator of nuclear genes involved in mitochondrial biogenesis 
and oxidative phosphorylation (Scarpulla 2006, Scarpulla 2008). Physiologically, 
changes in neuronal activity result in parallel changes in cellular metabolism, as well as 
the expression of NRF-1 and its associated control over mitochondrial biogenesis. In the 
rat pilocarpine-model of epilepsy, increased levels of NRF-1, and its upstream regulator 
PGC-1α, are observed in the face of mitochondrial impairment and/or dysfunction (Han, 
Lin et al. 2011). Furthermore, it has been reported that NRF-1 is a transcriptional 
activator of glutamate receptor subunit genes under conditions of depolarizing 
stimulation in neurons (Dhar and Wong-Riley 2009). So therefore, in addition to its role 
in cellular metabolism, via the regulation of the mitochondrial genome, evidence suggests 
that NRF-1 coordinates activities in the nucleus to couple neuronal excitability with 
energy demands of synaptic neurotransmission.  
Here, we ask whether NRF-1 may also affect synaptic transmission through 
control over the transcription of GABAR subunit genes, and in particular the human β1 
subunit gene, GABRB1, a gene that has been associated with neuronal developmental 
disorders, the pathophysiology of epilepsy, and alcohol dependence. In this study, we 
have uncovered a functional regulatory element within GABRB1 that demonstrates 
sequence specificity and is responsible for the majority of GABRB1 promoter-reporter 
activity in transfected primary cortical neurons. 
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C. Results 
1. Identification of a Conserved NRF1 Element in the GABRB1 Promoter 
 Previously, we mapped the 5’-regulatory region of GABRB1, identifying 
transcriptional start sites (TSSs) within a 10 bp functional initiator element (Inr) that 
mediates the response of the gene to chronic GABA (Russek, Bandyopadhyay et al. 2000, 
Saha, Hu et al. 2013). Now we report that directly upstream of this Inr is a canonical 
NRF-1 element spanning -11/+1 relative to the major TSS found for Gabrb1 expression 
in neocortical neurons. As shown in Figure 1, the location of the NRF-1 element within 
the promoter region is conserved across multiple species. Given the ubiquitous 
expression of NRF-1, its conservation across species, and its established role in 
metabolism and mitochondrial biogenesis, our sequence comparison strongly suggests 
that the NRF-1 element is functionally relevant to β1 subunit expression in the 
mammalian brain.  
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Figure 1. Sequence alignment of the 5’ region of β1 subunit gene promoters in 
reference to the ATG translational start site in multiple mammalian species. The β1 
subunit promoters contain a conserved NRF-1 element, which is indicated in bold type 
upstream of the major initiator element (Inr) that is underlined. Sequences were aligned 
using ClustalW, where conserved nucleotides are as indicated “*”. 
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2. NRF-1 Recognizes a Cis-Element in the GABRB1 Promoter 
 To determine the specific binding site within GABRB1-p that binds to NRF-1, we 
performed the electrophoretic mobility shift assay (EMSA) using a 32P-labeled probe that 
contains the NRF-1 binding element (Fig. 1) in reaction with the nuclear protein extracts 
from E18 primary cortical neurons. To validate the specificity of NRF-1 antibody for 
EMSA analysis, nuclear extracts were incubated with a positive control probe (Dhar, 
Ongwijitwat et al. 2008) containing the NRF-1 binding site of the rat cytochrome c 
promoter. As shown in lane 2 of Figure 2, the control radiolabeled probe (rat Cyt C) 
displays specific DNA recognition of binding proteins in nuclear extracts from cortical 
neurons that is confirmed by supershift with the addition of NRF-1 specific antibody 
(Fig. 2, lane 4). Next, specific binding to the putative NRF-1 in GABRB1 was confirmed 
using the same nuclear extracts, with sequence specificity defined by competition with an 
unlabeled double stranded oligonucleotide that was identical to the probe sequence 
(competitor) (Fig. 2, lanes 6 and 7). Addition of an unlabeled competitor mutant probe, 
containing substitutions within the GC core, failed to compete for complex formation 
(Fig. 2, lane 8). Presence of endogenous NRF-1 at its site in GABRB1 was further 
confirmed by supershift analysis using the NRF-1 specific antibody (Fig. 2, lane 9). 
Finally, a radiolabeled probe containing the sequence of the mutant NRF-1 site in 
GABRB1 shows little or no complex formation using the nuclear extracts under study 
(Fig. 2, lanes 10-12).   
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Figure 2. In vitro binding of NRF-1 to the putative NRF-1 site in GABRB1. 32P-
labeled probes encompassing the NRF-1 binding site were incubated with 20 μg of DIV7 
primary rat cortical nuclear extracts. 100-fold excess of unlabeled probe was added to the 
binding reaction to assess specificity. NRF-1 Abs were pre-incubated with nuclear 
extracts and radiolabeled probe to test for “supershift” and protein identification. (Left 
Panel) The NRF-1 element in the rat cytochrome c (Cyt C) promoter displays NRF-1 
specific binding (lane 2) and “supershift” (lane 4). (Right Panel) The proposed NRF-1 
element in the human GABRB1 promoter displays a probe specific shift (lane 6) (note 
excess probe was run off of the gel), competition of complex formation with cold 
competitor (lane 7), lack of competition with mutant cold competitor (lane 8), and 
supershift upon addition of NRF-1 specific Ab (lane 9).  In contrast, binding to 
radiolabeled probe for NRF-1 mutant GABRB1 shows markedly reduced signal (lanes 11 
and 12). “*” indicates specific interaction between labeled probe and nuclear extract, 
“←“ indicates location of supershift. 
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3. Overexpression of NRF1 Induces GABRB1 Promoter Activity in Transfected 
Primary Cortical Neurons 
 To evaluate whether there is a functional consequence to NRF-1 binding to its 
consensus site in GABRB1-p, primary cortical neurons were transfected with the 
GABRB1p-luciferase construct containing the 541 bp 5’ flanking region upstream of the 
human β1 subunit gene (Russek, Bandyopadhyay et al. 2000). We chose this approach to 
study functional relevance of the NRF-1 site to GABRB1 transcription because NRF-1’s 
influence on the genome is difficult to detect due to its robust expression at baseline and 
stability (Baar, Song et al. 2003, Scarpulla 2006, Ramachandran, Yu et al. 2008).  
 As the expression of NRF1:VP16 fusion proteins has been shown to induce the 
promoter activity of NRF-1 responsive genes in cell lines (Ramachandran, Yu et al. 2008, 
Gonen and Assaraf 2010), we transfected primary cortical neurons with NRF1:VP16 
expression constructs along with the GABRB1p-luciferase reporter and observed a 
marked increase (~70%) above baseline (when compared to co-transfection with empty 
vector control) (Fig. 3). Mutations were introduced into GABRB1-p using site-directed 
mutagenesis (based on the loss of specific binding of NRF-1 as identified in EMSA (see 
Fig. 2, lane 8)). As can be seen in Figure 3 for mGABRB1-p, with and without 
NRF1:VP16 overexpression, mutation of the NRF-1 regulatory element in GABRB1-p 
reduces basal activity to around 30% of wild type. Overexpression of NRF-1:VP16 has 
no effect on mGABRB1-p, showing that increased GABRB1 promoter activity directed by 
NRF-1 is sequence specific; and, moreover, that NRF-1 may be an important positive 
regulator of β1 subunit expression in developing neurons, especially interesting because 
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β1 is found in the germinal zones and associated with pre-migrating neurons (Ma and 
Barker, 1995) and increased mitochondrial biogenesis has also been associated with 
neuronal differentiation (Vayssiere, Cordeau-Lossouarn et al. 1992, Cheng, Hou et al. 
2010). 
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Figure 3. Overexpression of NRF-1:VP16 increases GABRB1 promoter activity in a 
sequence specific manner. Primary cortical neurons were co-transfected with 2 µg of 
wild type GABRB1p (wtGABRB1p) or the NRF-1 binding site mutant (mGABRB1p) and 1 
μg of empty vector pcDNA3 or the NRF-1:VP16 fusion construct. Cells were assayed for 
luciferase activity 24 hours after transfection. Data represent the average ± SEM (n = 5 
independent transfections) of luciferase activity relative to wild type GABRB1p in the 
absence of NRF-1:VP16. “*”and “ns” represent significance based on p < 0.05 and not 
significant, respectively, according to Student’s t-test. 
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4. Inhibition of NRF-1 Function in Neurons 
 
 To evaluate the direct contribution of endogenous NRF-1 to the regulation of 
GABRB1-p, NRF-1 expression constructs were co-transfected with vectors containing 
putative NRF-1 targeted shRNAs, or scrambled negative control shRNAs, in HEK cells 
to identify shRNAs that could be used subsequently for NRF-1 silencing in primary 
neurons. NRF-1 shRNA8 exhibited ~50% knockdown of NRF-1 protein levels (Fig. 4). 
Therefore, GABRB1 promoter activity was assayed in the presence of either NRF-1 
shRNA8 or NRF-1 shRNA9 in transfected primary cortical neurons. As can been seen in 
the upper panel of Figure 5, co-transfection of the promoter construct with shRNA8 led 
to a small but significant ~20% reduction in GABRB1-p as compared to the scrambled 
shRNA control (Fig. 5A).  
 To further evaluate the specific effect of NRF-1 on GABRB1 transcription, we 
utilized a dominant negative form of NRF-1 that contains the DNA binding domain but 
lacks the trans-activation domain (Gugneja, Virbasius et al. 1996). Co-expression of 
dominant negative NRF-1 represses GABRB1 promoter activity by 45% (Fig. 5B). When 
taken together with the fact that the NRF-1 element in the β1 subunit gene is completely 
conserved across species, and that there is a mutational loss of binding and function as 
assayed in transfected primary neurons, our results strongly suggest that NRF-1 is an 
essential feature of β1 subunit expression in neurons. 
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Figure 4. Silencing efficiency of NRF-1 shRNAs in HEK293 cells. (Top Panel) HEK 
cells in 6-well plates were co-transfected with NRF-1 expression constructs (0.5 µg) and 
vectors containing NRF-1 targeted (1 µg) or random sequence (RS) shRNAs. Forty-eight 
hours after transfection, total proteins were extracted and monitored for NRF-1 and β-
actin expression. A representative western blot is shown. (Bottom Panel) NRF-1 levels 
were quantified by densitometry and normalized to levels of β-actin. NRF-1 abundance is 
expressed relative to RS control. Data represent the average ± SEM of n = 3 independent 
transfections. “*”, p < 0.05,  Student’s t-test. NRF-1 shRNAs8 and 9 were chosen for 
NRF-1 silencing in transfected primary cortical neurons. 
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Figure 5. Overexpression of dominant negative NRF-1 and application of NRF-1 
directed shRNAs reduce GABRB1 promoter activity in transfected primary cortical 
neurons. (A) Primary cortical neurons were co-transfected with GABRB1p and NRF-1 
shRNA constructs. Forty-eight hours after transfection, cells were assayed for luciferase 
activity. Data represent the average ± SEM of n = 3 independent transfections, 
normalized to wild type GABRB1p-luciferase and random sequence (RS) shRNA. **, p < 
0.01, Student’s t-test. (B) Primary cortical neurons were co-transfected with either 
pcDNA3 or a dominant negative variant of NRF-1 (NRF-1 DN) and the GABRB1p 
reporter (2 µg). Twenty-four hours after transfection, cells were assayed for luciferase 
activity. Data represent the average ± SEM of n = 6 independent transfections, 
normalized to wild type GABRB1p and the pcDNA3 control. *, p < 0.05, Student’s t-test. 
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D. Discussion 
The results of these studies in primary cortical neurons strongly suggest that the 
GABAR β1 subunit gene is regulated by NRF-1, a crucial transcription factor involved in 
oxidative phosphorylation and mitochondrial biogenesis. Here, we expatiate the role of 
NRF-1 in coordinating synaptic activity and energy metabolism beyond that of 
glutamatergic neurotransmission (Dhar, Liang et al. 2009, Dhar and Wong-Riley 2009, 
Dhar and Wong-Riley 2011), extending it to selective inhibitory GABAergic 
neurotransmission that may be relevant to brain disorders where β1 is implicated.   
Previously, our laboratory mapped the 5’ flanking region of the human β1 subunit 
promoter. Within this TATA-less promoter, we identified the major transcriptional start 
site (TSS) and described an initiator element (Inr) that senses the presence of prolonged 
GABA to mediate the autologous downregulation of β1 subunit expression (Russek, 
Bandyopadhyay et al. 2000). Our recent studies have discovered that such decreases in β1 
subunit RNA levels may reflect a change in the chromatin state as mediated by PhF1b, a 
polycomb-like protein (Saha, Hu et al. 2013). In our present work, we have found a 
conserved canonical NRF-1 binding element (Fig. 1) that interacts with NRF-1 in vitro as 
verified by mobility shift assays (Fig. 2).  Interestingly, our results are consistent with a 
peak of NRF-1 binding in embryonic stem cells H1-hESC as archived in the ENCODE 
database (Gerstein, Kundaje et al. 2012, Wang, Zhuang et al. 2012, Wang, Zhuang et al. 
2013) (http://genome.ucsc.edu/).  This significant peak for NRF-1 is located immediately 
upstream of the β1 Inr element and associated major TTS.  
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It is thought that NRF-1 binds as a homodimer to the consensus binding sequence 
(T/C)GCGCA(C/T)GCGC(A/G), making contact with DNA at the guanine nucleotides 
(Virbasius, Virbasius et al. 1993). This model is supported by the results of our 
mutational studies that show that a single mutation of G->C eliminates that ability of a 
cold double stranded oligonucleotide to compete for complex formation as assayed by 
mobility shift. The location of the NRF-1 element in GABRB1 centers at -12 relative to 
the major TTS in neocortical neurons.  The GC-rich NRF-1 binding motif is often 
associated with TATA-less promoters and found within 100 bp DNA regions around 
transcriptional start sites in the human genome (Virbasius, Virbasius et al. 1993, Xi, Yu 
et al. 2007). The proximity of the NRF-1 element in GABRB1 to the Inr that binds PCL 
proteins associated with chromatin remodeling and DNA methylation (Vire, Brenner et 
al. 2006) may underlie its major role in controlling basal levels of β1 subunits in neurons. 
Whether GABRB1 is epigenetically regulated remains to be determined and could be a 
feature of why its transcription decreases in disease, especially since NRF-1 binding is 
blocked by DNA methylation (Gebhard, Benner et al. 2010).   
Using the sensitivity of the luciferase reporter system, we have exploited the 
knockdown of endogenous NRF-1 in primary neurons to confirm the results of promoter 
mutational studies both with overexpressed NRF-1:VP16 in living neurons and in in vitro 
in binding assays where mutations disrupt NRF-1 specific recognition. Our results are 
consistent with previous studies from our laboratory, using the same wild type 
GABRB1p-luciferase reporter construct, where promoter truncation and/or deletion that 
removes the Inr and disrupts the element for NRF-1 results in a 75-90% decrease in 
  
62 
luciferase gene transcription (Russek, Bandyopadhyay et al. 2000) (Fig. 3). Given that 
GABAR blockade by bicuculine has also been shown to drive NRF-1 dependent 
transcription (Delgado and Owens 2012) and that bicuculine reverses GABA-induced 
downregulation of β1 mRNA levels (Russek, Bandyopadhyay et al. 2000), presumably 
through PhF1b binding to the Inr, our new results suggest that the NRF-1 responsive 
element and Inr may act synergistically to regulate β1 subunit levels as neurons adapt to 
changes in their activity state. 
Although differential expression of α subunits in relationship to brain disorders 
has clearly been associated with their region specific changes in tonic and phasic 
inhibition, it is only recently that the importance of differential β subunit containing 
GABARs has been noted. This selective property of GABARs controlled by β subunit 
expression, however, has been limited to β2 and β3, with β1 present in only a limited 
population of receptors in the brain. However of all β subunits, β1 has been mostly 
associated with both neurological and neuropsychiatric disorders. The reason for this 
functional relationship remains to be described and is an active area of investigation in 
our laboratory. 
Recent identification of fragrant dioxane derivatives that show a 6-fold preference 
for β1-containing GABARs (Sergeeva, Kletke et al. 2010) suggest that the β1 subunit is 
required for the modulation of wakefulness that is mediated by the histaminergic neurons 
of the posterior hypothalamus (tubermamillary nucleus-TMN) (Yanovsky, Schubring et 
al. 2012). Given that energy metabolism is sensitive to restoration during the sleep cycle 
and that NRF-1 levels rise with sleep deprivation (Nikonova, Naidoo et al. 2010), it is 
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interesting that β1-containing receptors are the major source of inhibitory control over 
sleep.  
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CHAPTER IV. A Biosensor for CREB Activation in vivo Responds to BDNF and 
PKA Signaling 
 
A. Abstract   
 Determining the individual contribution of neurons to the output of vast multi-
cellular brain networks is paramount in neuroscience. We have employed a protein-
protein interaction reporter system, based on the firefly luciferase protein, to track the 
activation of the memory molecule cAMP-response element binding protein (CREB) in 
living primary cortical neurons, as a first step to integrating principles of molecular 
dynamics into systems neuroscience. The luciferase enzyme is split into N- and C- 
terminal fragments, which are fused to the kinase interacting domain (KIX) of the CREB-
binding protein (CBP) and the kinase-inducible domain of the cAMP-response element 
binding protein (CREB), respectively. Luciferase is reconstituted and its activity is 
restored upon the phosphorylation of KID and its subsequent binding with KIX. Using 
this biosensor, we observe CREB activation and recruitment of CBP (in response to 
forskolin-induced cAMP production) that is attenuated with alanine mutation at Serine 
133 (S133A).  Activation of CREB and recruitment of CBP via BDNF is also detected 
and while attenuated by the S133A mutation in KID, there is still a persistent emission of 
light suggesting a contribution of additional regulatory features to the program of CREB 
regulation in living neurons.  In addition, our studies using this novel biosensor have 
revealed that the inducible cAMP early repressor (ICER), a known repressor of CREB 
target genes, can exert its repressor effects by disrupting the ability of phosphorylated 
CREB to recruit CBP rather than acting solely at the level of DNA.  This technology, 
therefore, has the promise of providing a platform for researchers to track CREB-
  
65 
activated transcription within a neural network, as well as to characterize regulators of 
CREB-CBP interactions and CREB function in vivo.  
B. Introduction 
The function of cyclic adenosine monophosphate (cAMP) response element-
binding protein (CREB) is essential in the formation of long-term memory as mediated 
by the hippocampus and the amygdala (Montminy and Bilezikjian 1987). Moreover, the 
relative level of activated CREB has also been associated with the selection of neurons 
for inclusion in a circuit that is believed to underlie a memory trace (Han, Kushner et al. 
2007). When phosphorylated at a key residue in the protein, CREB acts as a 
transcriptional regulator binding to the promoter region of particular genes that contain 
the canonical cAMP Response Element (CRE). Upon binding and activation, a diversity 
of cofactors and components of the transcriptional machinery are recruited to promote the 
stabilization of RNA Polymerase II to the initiator sequence and subsequent RNA 
synthesis. 
 Activation of CREB occurs in response to multiple signaling pathways that are 
activated by synaptic transmission. An important residue on the protein that is 
responsible for the majority of CREB activation is serine 133 (S133). After 
phosphorylation at this residue, CREB associates with its co-activator, the CREB-binding 
protein (CBP) via the CBP kinase inducible interacting (KIX) domain, which helps to 
stabilize the pre-initiation complex on the open promoter to initiate transcription. Serine 
133 is located within the kinase-inducible domain (KID) of CREB, where the activity of 
a variety of kinases, including protein kinase A (PKA), calcium-calmodulin-dependent 
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protein kinase (CaMK), and mitogen-activated protein kinase kinase (MEK), converge to 
regulate the protein’s function via post-translational modifications that can either lead to 
activation or repression. Most detailed studies of CREB function in neurons have been 
done in vitro using immunohistochemistry or Western blot analysis. Little is known about 
the dynamic changes that occur in its activation and inactivation in living cells and 
whether there is specificity to such regulation dependent upon extracellular signals and 
the intracellular pathways they control.  Therefore, we reasoned that by monitoring the 
interaction of KID-KIX in living neurons and subsequently in a living organism, we 
might be able to better study the underlying properties of its tight control over synaptic 
plasticity and the neural circuits that are associated with its role in memory formation.  
 Here, I report implementation of a genetic biosensor that will enable us to 
visualize dynamic KID-KIX interactions in primary cultured neurons as a first step 
towards developing a molecular tool for future use in animal models.  We have utilized 
the firefly luciferase complementation bioluminescence (BLI) system as our strategy to 
detect KID-KIX interactions in living neurons. This system has the advantages of 
maintaining good cellular viability and an outstanding signal-to-noise detection ratio. In 
brief, the activity of the reporter enzyme luciferase is disrupted by separating it into two 
components, where each is fused to a domain of interest on CREB and CBP. Under 
conditions of CREB phosphorylation, such as neural stimulation or kinase activation, 
KID and KIX will associate and the enzymatic activity of the luciferase reporter will be 
reconstituted so that application of substrate into the media will lead to the emission of 
light.   
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C. Results 
1. Forskolin and BDNF Stimulate the KID-KIX Interaction in Cultured Cortical 
Neurons.  
 Forskolin (FSK) is a known activator of adenylyl cyclase, an enzyme that 
converts ATP into the second messenger cAMP that activates the cAMP-dependent 
Protein Kinase A (PKA), which phosphorylates CREB at S133.  Serine 133 
phosphorylation then stimulates the recruitment of the CBP/p300 co-activator. To 
validate this established protein-protein interaction at the KID and KIX domains in 
neurons, we treated cultured primary cortical neurons, transiently expressing KID-LucC 
and KIX-LucN, with either DMSO (vehicle control) or 20 µM FSK for 2 h. Under these 
conditions, FSK stimulates the KID-LucC/KIX-LucN interaction (as measured by light 
emission) in cultured primary cortical neurons by 4-fold, as compared to the vehicle 
control. This stimulation is significantly reduced (~65%) when the KID-LucC construct 
contains the S133A mutation (Fig. 6).  
 Brain-derived neurotrophic factor (BDNF) is a major signaling molecule in the 
nervous system that is intimately connected to cell survival, the formation of synapses, 
the development of neurites and their maintenance (Kwon, Fernandez et al. 2011), as well 
as spatial learning (Mizuno, Yamada et al. 2000). Endogenous expression of BDNF is 
activity-dependent and induces CREB activation at S133 in vivo (Ying, Futter et al. 
2002). Individual expression of either KID-LucC or KIX-LucN does not elicit luciferase 
activity (light emission) in the presence of BDNF (Fig. 7A). However, when they are co-
expressed to generate the KID-KIX interaction there is a dose dependent increase in light 
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at ~5-fold over baseline at 10 ng/ml (20 nM) BDNF and 12-fold over baseline at 50 
ng/ml (100 nM)  BDNF (Fig. 7B). The 100 nM BDNF-stimulated KID-KIX interaction is 
attenuated ~50% upon mutation of S133 to A133 in KID-LucC compared to wild type.  
As shown in Figure 8, the emission of light can also be detected in individual transfected 
neurons using bioluminescence microscopy (LV200 Olympus BLI microscope) 
suggesting that in the future this biosensor may prove important for the specific detection 
of individual neurons within a circuit whose gene expression program is being modified 
by synaptic activity.  
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Figure 6. Forskolin induces a KID-CLuc/KIX-NLuc interaction in cultured primary 
cortical neurons. Neurons in a 96-well format were transfected with either wild type or 
S133A mutant KID-CLuc and KIX-NLuc pairs. Wells were treated with either vehicle or 
forskolin (20 μM) for 2 h before Xenogen IVIS imaging. A representative IVIS 
bioluminescence image of live neurons in pseudocolor for one N is shown on left. ** p < 
0.01; Error bars represent mean ± SEM of at least 3 independent cultures where each N 
contained duplicate or triplicate wells.  
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Figure 7. BDNF induces a KID-CLuc/KIX-NLuc interaction in cultured primary 
cortical neurons that is partially reversed with S133A mutation.  (A) Neurons grown 
in a 96-well format were transfected with either KID-CLuc or KIX-Nluc and treated with 
BDNF (50 ng/ml). (B) Neurons were transfected with KID-CLuc and KIX-NLuc and 
then treated with vehicle, low concentration (10 ng/ml), or high concentration (50 ng/ml) 
of BDNF. (C) Neurons were transfected with either wild type or S133A mutant KID-
CLuc and KIX-NLuc pairs. Wells were treated with either vehicle or BDNF (50 ng/ml) 2 
h prior to IVIS imaging. IVIS bioluminescence images of live neurons in pseudocolor are 
shown. * p < 0.05, “n.s.” = not significant; Error bars represent mean ± SEM of at least 3 
independent cultures where each N is from duplicate or triplicate wells.  
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Figure 8. Bioluminescence detection induced by BDNF in individual transfected 
neurons containing KID-CLuc and KIX-NLuc expression constructs.  Primary 
cortical neurons were transfected with KID-CLuc and KIX-NLuc and then treated with 
vehicle (top panel) or BDNF (50 ng/ml) (bottom panel) for 2 h. Merged bright field and 
bioluminescence images represent sampling of different fields within a single dish. 
Bioluminescent signal is indicated by cyan blue and was visualized using the Olympus 
LV200 bioluminescence imaging system. 
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2. ICER IIγ may inhibit the association between KID and KIX  
 Similar to CREB, CREM (the cAMP response element modulator) is a cAMP-
responsive nuclear factor that binds to CRE containing promoters. Unlike the 
ubiquitously expressed CREB, the expression of the CREM gene product is cell-type and 
developmentally specific (Misund, Steigedal et al. 2007). A splice variant of CREM 
gives rise to the gene product ICER IIγ (Inducible cAMP Early Repressor); a nuclear 
factor that contains a CRE binding domain but lacks the transcriptional activation domain 
of CREM. Our lab has previously shown that induction of ICER IIγ expression reduces 
CREB activation of the promoter for the type A GABA receptor 1 subunit gene (Lund, 
Hu et al. 2008). Preliminary data now shows that there may be an interesting relationship 
between CREB and ICER at the level of CREB/CBP interactions that is independent of 
the CRE site (Fig. 4), as overexpression of ICER IIγ is trending towards a decrease in the 
BDNF induced KID-KIX association from 5-fold to 2.5-fold. 
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Figure 9. ICER IIγ over-expression may attenuate the BDNF-induced KID-KIX 
association in primary cultured neurons. Cells were triple-transfected with either 
pcDNA3 (empty vector) or ICER IIγ expression plasmids, and the KID-CLuc and KIX-
NLuc pair. Both groups were treated with vehicle or BDNF (100 nM) for 2 h before IVIS 
imaging. An IVIS bioluminescence image of live neurons in pseudocolor is shown. * p < 
0.05; Error bars represent mean ± SEM of at least 3 independent cultures where each N 
contained duplicate or triplicate wells.  
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Discussion 
 In this report we demonstrate that induced KID-KIX interactions can be 
visualized in primary cultured neurons using the Xenogen IVIS imaging system and the 
LV200 Olympus BLI microscope to detect single neuron light emission.  Results from 
the BDNF-mediated KID-KIX interaction suggests that there may be other regulatory 
residues responsible for the CREB-CBP association in living neurons as S133A does not 
completely block association between the protein domains. The trending loss of light 
emission after over-expression of ICER IIγ suggests that ICER may associate with KID 
or KIX to repress CREB-mediated gene expression.  This is a new observation and given 
the role of ICER in processes of learning and memory, especially long term depression 
(LTD) (Mioduszewska, Jaworski et al. 2003, Kojima, Borlikova et al. 2008) it may 
indicate a new area for future research and the development of target therapeutic 
molecules as cognitive enhancers.  
 Future studies will be aimed at the use of this novel biosensor in vivo to map the 
specific neurons in a circuit whose genome is being altered in response to synaptic 
activity over time.  In order for this to happen one must employ a sensitive means to 
detect light emission in the living animal, an area currently being developed in the 
laboratory of Tim Gardner at Boston University that will be used to test the principles of 
this particular protein reconstitution approach in collaboration with our laboratory. These 
biosensors can also be used to signal the activation of particular intracellular pathways 
when coupled to the mutation of certain residues that are pathway specific; for instance, 
to distinguish between PKA signaling vs that of mitogen activated protein kinase 
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(MAPK).  Finally, these approaches can also be applied to other important interacting 
molecules that are of great significance to the field of molecular neuroscience so that 
their dynamics can be studied in vivo to determine the implication of such interactions to 
systems neuroscience.  
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APPENDIX 
 Altered expression of GABAA receptors (GABAR) containing α4 subunit has 
been implicated in both physiologic and pathologic processes, such as learning and 
memory, alcohol withdrawal, and temporal lobe epilepsy (TLE). In particular, up-
regulation of α4 subunit expression has been observed in both TLE patients and animal 
models of TLE. One aspect of α4 containing GABAARs is that they control the majority 
of tonic inhibition in the brain, an important feature of synaptic plasticity and neuronal 
excitability. Moreover, in the face of α1 subunit down regulation 24 hours after status 
epilepticus (SE), α4/β2/γ2 containing GABARs appear at the synapse. Due to the critical 
importance of α4 subunits in the normal brain and the pathophysiology of epilepsy, a 
detailed understanding of the molecular mechanisms regulating its expression becomes 
increasingly significant.  
 In this pursuit, we used bioinformatic tools to identify novel regulatory elements 
in GABAR subunit promoters. We have identified putative binding sites within the 
GABRA4 promoter for NRF-1. Our preliminary results in primary cortical cultures show 
that NRF-1 is up-regulated by BDNF stimulation, NRF-1 binds to the human GABRA4 
promoter (GABRA4-p) in vitro, and that activation of NRF-1 gene expression through 
depolarizing stimulation also resulted in a significant increase in the expression of rat 
Gabra4. Taken together, these observations have led us to hypothesize that NRF-1 
directly regulates GABAAR α4 subunit expression at the transcriptional level. The results 
of these studies should further our understanding of the role that activity plays in 
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regulating α4 subunit levels, expand on the role of NRF-1 in synaptic transmission, and 
explore lines of inquiry into mitochondrial biogenesis in epilepsy. 
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Figure A1. In vitro interactions between NRF-1 and human GABRA4 subunit 
promoter. 32P-labeled probes corresponding to NRF-1 putative binding sites were 
incubated with 20μg of nuclear extract. 100-fold excess unlabeled probes pre-incubated 
with nuclear extracts serve as specific competitors. NRF-1 antibodies were pre-incubated 
with nuclear extracts to form specific binding complexes that result in a supershift. The 
positive control Rat cytochrome c probe has specific shift (lane 3) and supershift (lane 4). 
Human GABRA4 Probe, containing the putative binding sequence 5’ 
GCAGCGCAAGCGCGCGG 3’, has specific shift (lane 7) and supershift (lane 8). 
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Figure A2. Induction of NRF-1 and Gabra4 mRNA expression by KCl 
depolarization of primary cortical neurons. Primary cortical cultures were treated with 
either control or 20 mM KCl for 6 hours. Following treatment, cells were collected for 
analysis by qRT-PCR with primers and probes designed to NRF-1 and Gabra4. Samples 
were standardized to cyclophilin. (n=5) **p<0.01 
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Figure A3. Induction of NRF-1 protein expression by KCl depolarization of primary 
cortical neurons. Primary cortical cultures were treated with either control or 20 mM 
KCl for 6 and 12 hours. Following treatment, cell extracts were collected for western blot 
analysis and probed for NRF-1 levels. Samples were standardized to β-actin levels. (n=4) 
*p<0.05 
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Figure A4: Induction of NRF-1 and Gabra4 mRNA expression by BDNF 
stimulation of primary cortical neurons. Primary cortical cultures were treated with 
either vehicle or 50 ng/ml BDNF for 6 hours. Following treatment, cells were collected 
for analysis by qRT-PCR with primers and probes designed to NRF-1 and Gabra4. 
Samples were standardized to cyclophilin. (n=4) *p<0.05 
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Figure A5. Levels of NRF-1 increases in rat hippocampus 24 h after status 
epilepticus (SE) in the pilocarpine rat model of TLE. (Control n=3, SE n=4) * p<0.05.  
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